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Abstract
Accurate prediction of progression in subjects at risk of Alzheimer’s disease is crucial for enrolling the
right subjects in clinical trials. However, a prospective comparison of state-of-the-art algorithms for
predicting disease onset and progression is currently lacking. We present the findings of The Alzheimer’s
Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge, which compared the performance
of 92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at
risk of Alzheimer’s disease. Challenge participants were required to make a prediction, for each month
of a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer’s Disease Assessment
Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. No single submission
was best at predicting all three outcomes. For clinical diagnosis and ventricle volume prediction, the
best algorithms strongly outperform simple baselines in predictive ability. However, for ADAS-Cog13
no single submitted prediction method was significantly better than random guessing. On a limited,
cross-sectional subset of the data emulating clinical trials, performance of best algorithms at predicting
clinical diagnosis decreased only slightly (3% error increase) compared to the full longitudinal dataset.
Two ensemble methods based on taking the mean and median over all predictions, obtained top scores
on almost all tasks. Better than average performance at diagnosis prediction was generally associated
with the additional inclusion of features from cerebrospinal fluid (CSF) samples and diffusion tensor
imaging (DTI). On the other hand, better performance at ventricle volume prediction was associated
with inclusion of summary statistics, such as patient-specific biomarker trends. The submission system
remains open via the website https://tadpole.grand-challenge.org, while code for submissions is
being collated by TADPOLE SHARE: https://tadpole-share.github.io/. Our work suggests that
current prediction algorithms are accurate for biomarkers related to clinical diagnosis and ventricle
volume, opening up the possibility of cohort refinement in clinical trials for Alzheimer’s disease.
1 Introduction
Accurate prediction of the onset of Alzheimer’s disease (AD) and its longitudinal progression is important
for care planning and for patient selection in clinical trials. Current opinion holds that early detection
will be critical for the successful administration of disease modifying treatments during presymptomatic
phases of the disease prior to widespread brain damage, e.g. when pathological amyloid and tau start
to accumulate [1]. Moreover, accurate prediction of the progression of at-risk subjects will help select
homogenous patient groups for clinical trials, thus reducing variability in outcome measures that can
obscure positive effects on patients at the right stage to benefit.
Several mathematical and computational methods have been developed to predict the onset and
progression of AD. Traditional approaches leverage statistical regression to model relationships between
target variables (e.g. clinical diagnosis or cognitive/imaging markers) with other known markers [2, 3]
or measures derived from these markers such as the rate of cognitive decline [4]. More recent approaches
involve supervised machine learning techniques such as support vector machines, random forests and
artificial neural networks. These approaches have been used to discriminate AD patients from cognitively
normal individuals [5, 6], and for discriminating at-risk individuals who convert to AD in a certain
time frame from those who do not [7, 8]. The emerging approach of disease progression modelling
aims to reconstruct biomarker trajectories or other disease signatures across the disease progression
timeline, without relying on clinical diagnoses or estimates of time to symptom onset. Examples include
models built on a set of scalar biomarkers to produce discrete [9, 10] or continuous [11, 12, 13, 14, 15]
biomarker trajectories; spatio-temporal models that focus on evolving image structure [16, 17], potentially
conditioned by non-imaging variables [18]; and models that emulate putative disease mechanisms to
estimate trajectories of change [19, 20, 21]. All these models show promise for predicting AD biomarker
progression at group and individual levels. However, previous evaluations within individual publications
provide limited information because: (1) they use different data sets or subsets of the same dataset,
different processing pipelines, and different evaluation metrics and (2) over-training can occur due to
heavy use of popular training datasets. Currently, the field lacks a comprehensive comparison of the
capabilities of these methods on standardised tasks relevant to real-world applications.
Community challenges have consistently proved effective in moving forward the state of the art in
technology to address specific data-analysis problems by providing platforms for unbiased comparative
of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI
investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_
List.pdf
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evaluation and incentives to maximise performance on key tasks [22]. In medical image analysis, for
example, such challenges have provided important benchmarks in tasks such as registration [23] and seg-
mentation [24], and revealed fundamental insights about the problem studied, for example in structural
brain-connectivity mapping [25]. Previous challenges in AD include the CADDementia challenge [26],
which aimed to identify clinical diagnosis from MRI scans. A similar challenge, the International chal-
lenge for automated prediction of MCI from MRI data [27], asked participants to predict diagnosis and
conversion status from extracted MRI features of subjects from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) study [28]. Yet another challenge, The Alzheimer’s Disease Big Data DREAM Chal-
lenge [29], asked participants to predict cognitive decline from genetic and MRI data. These challenges
have however several limitations: (i) they did not evaluate the ability of algorithms to predict biomarkers
at future timepoints (with the exception of one sub-challenge of DREAM), which is important for patient
stratification in clinical trials; (ii) the test data was available to organisers when the competitions were
launched, leaving room for potential biases in the design of the challenges; (iii) the training data was
drawn from a limited set of modalities.
The Alzheimer’s Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge (https://
tadpole.grand-challenge.org) aims to identify the data, features and approaches that are the most
predictive of future progression of subjects at risk of AD. In contrast to previous challenges, our challenge
is designed to inform clinical trials through identification of patients most likely to benefit from an
effective treatment, i.e., those at early stages of disease who are likely to progress over the short-to-
medium term (1-5 years). The challenge focuses on forecasting the trajectories of three key features:
clinical status, cognitive decline, and neurodegeneration (brain atrophy), over a five-year timescale.
It uses “rollover” subjects from the ADNI study [28] for whom a history of measurements (imaging,
psychology, demographics, genetics) is available, and who are expected to continue in the study, providing
future measurements for testing. TADPOLE participants were required to predict future measurements
from these individuals and submit their predictions before a given submission deadline. Since the test
data did not exist at the time of forecast submissions, the challenge provides a performance comparison
substantially less susceptible to many forms of potential bias than previous studies and challenges. The
design choices were published [30] before the test set was acquired and analysed. TADPOLE also goes
beyond previous challenges by drawing on a vast set of multimodal measurements from ADNI which
might support prediction of AD progression.
This article presents the results of the TADPOLE Challenge and documents its key findings. We
summarise the challenge design and present the results of the 92 prediction algorithms contributed by
33 participating teams worldwide, evaluated after an 18-month follow-up period. We discuss the results
obtained by TADPOLE participants, which represent the current state-of-the-art in Alzheimer’s disease
prediction. To understand what key characteristics of algorithms were important for good predictions,
we also report results on which input data features were most informative, and which feature selection
strategies, data imputation methods and classes of algorithms were most effective.
2 Results
2.1 Predictions
TADPOLE Challenge asked participants to forecast three key biomarkers: (1) clinical diagnosis, which
can be either cognitively normal (CN), mild cognitive impairment (MCI), or probable AD; (2) Alzheimer’s
Disease Assessment Scale Cognitive Subdomain (ADAS-Cog13) score; and (3) ventricle volume (divided
by intra-cranial volume) from MRI. The exact time of future data acquisitions for any given individual was
unknown at forecast time, so participants submitted month-by-month predictions for every individual.
Predictions of clinical status comprise relative likelihoods of each option (CN, MCI, and AD) for each
individual at each month. Predictions of ADAS-Cog13 and ventricle volume comprise a best-guess
estimate as well as a 50% confidence interval for each individual at each month. Full details on challenge
design are given in the TADPOLE white paper [30].
2.2 Algorithms
We had a total of 33 participating teams, who submitted a total of 58 predictions from the longitudinal
prediction set (D2), 34 predictions from the cross-sectional prediction set (D3), and 6 predictions from
custom prediction sets (see Online Methods section 5.1 for description of D2/D3 datasets). A total
of 8 D2/D3 submissions from 6 teams did not have predictions for all three target variables, so we
3
Submission
Feature
selection
Number of
features
Missing data
imputation
Diagnosis prediction
model
ADAS/Vent.
prediction model
Training
time
Prediction
time (one
subject)
AlgosForGood manual 16+5* forward-filling Aalen model linear regression 1 min. 1 sec.
Apocalypse manual 16 population average SVM linear regression 40 min. 3 min.
ARAMIS-Pascal manual 20 population average Aalen model - 16 sec. 0.02 sec.
ATRI-Biostat-JMM automatic 15 random forest random forest
linear mixed effects
model
2 days 1 sec.
ATRI-Biostat-LTJMM automatic 15 random forest random forest DPM 2 days 1 sec.
ATRI-Biostat-MA automatic 15 random forest random forest
DPM + linear mixed
effects model
2 days 1 sec.
BGU-LSTM automatic 67 none feed-forward NN LSTM 1 day millisec.
BGU-RF/ BGU-RFFIX automatic ≈ 67+1340* none semi-temporal RF semi-temporal RF a few
min.
millisec.
BIGS2 automatic all
Iterative
Thresholded SVD
RF linear regression 2.2 sec. 0.001 sec.
Billabong (all) manual 15-16 linear regression linear scale non-parametric SM 7 hours 0.13 sec.
BORREGOSTECMTY automatic ≈100 + 400* nearest-neighbour regression ensemble ensemble of regression
+ hazard models
18 hours 0.001 sec.
BravoLab automatic 25 hot deck LSTM LSTM 1 hour a few sec.
CBIL manual 21 linear interpolation LSTM LSTM 1 hour one min.
Chen-MCW manual 9 none linear regression DPM 4 hours < 1 hour
CN2L-NeuralNetwork automatic all forward-filling RNN RNN 24 hours a few sec.
CN2L-RandomForest manual >200 forward-filling RF RF 15 min. < 1 min.
CN2L-Average automatic all forward-filling RNN/RF RNN/RF 24 hours < 1 min.
CyberBrains manual 5 population average linear regression linear regression 20 sec. 20 sec.
DIKU (all)
semi-
automatic
18 none
Bayesian classifier/LDA
+ DPM
DPM 290 sec. 0.025 sec.
DIVE manual 13 none KDE+DPM DPM 20 min. 0.06 sec.
EMC1 automatic 250 nearest neighbour
DPM + 2D spline +
SVM
DPM + 2D spline 80 min. a few sec.
EMC-EB automatic 200-338 nearest-neighbour SVM classifier SVM regressor 20 sec. a few sec.
FortuneTellerFish-Control manual 19 nearest neighbour multiclass ECOC SVM
linear mixed effects
model
1 min. < 1 sec.
FortuneTellerFish-SuStaIn manual 19 nearest neighbour
multiclass ECOC SVM
+ DPM
linear mixed effects
model + DPM
5 hours < 1 sec.
Frog automatic ≈ 70+420* none gradient boosting gradient boosting 1 hour -
GlassFrog-LCMEM-HDR
semi-
automatic
all
forward-
fill/nearest-neigh.
multi-state model DPM + regression 15 min. 2 min.
GlassFrog-SM manual 7 linear model multi-state model parametric SM 93 sec. 0.1 sec.
GlassFrog-Average
semi-
automatic
all forward-fill/linear multi-state model
DPM + SM +
regression
15 min. 2 min.
IBM-OZ-Res manual Oct-15 filled with zero
stochastic gradient
boosting
stochastic gradient
boosting
20 min. 0.1 sec.
ITESMCEM manual 48
mean of previous
values
RF
LASSO + Bayesian
ridge regression
20 min. 0.3 sec.
lmaUCL (all) manual 5 regression multi-task learning multi-task learning 2 hours millisec.
Mayo-BAI-ASU manual 15 population average
linear mixed effects
model
linear mixed effects
model
20 min. 1.3 sec.
Orange manual 17 none clinician’s decision tree clinician’s decision tree none 0.2 sec.
Rocket manual 6
median of
diagnostic group
linear mixed effects
model
DPM 5 min. 0.3 sec.
SBIA manual 30-70
dropped visits with
missing data
SVM + density
estimator
linear mixed effects
model
1 min. a few sec.
SPMC-Plymouth (all) automatic 20 none unknown - unknown 1 min.
SmallHeads-NeuralNetwork automatic 376 nearest neighbour
deep fully -connected
NN
deep fully -connected
NN
40 min. 0.06 sec.
SmallHeads-LinMixedEffects automatic unknown nearest neighbour -
linear mixed effects
model
25 min. 0.13 sec.
Sunshine (all)
semi-
automatic
6 population average SVM linear model 30 min. < 1 min.
Threedays manual 16 none RF - 1 min. 3 sec.
Tohka-Ciszek-SMNSR manual ≈ 32 nearest neighbour - SMNSR several
hours
a few sec.
Tohka-Ciszek-RandomForestLin
manual 32 mean patient value RF linear model
a few
min.
a few sec.
VikingAI (all) manual 10 none
DPM + ordered logit
model
DPM 10 hours 8 sec.
BenchmaskLastVisit None 3 none constant model constant model 7 sec. millisec.
BenchmarkMixedEffects None 3 none Gaussian model
linear mixed effects
model
30 sec. 0.003 sec.
BenchmarkMixedEffects-APOE
None 4 none Gaussian model
linear mixed effects
model
30 sec. 0.003 sec.
BenchmarkSVM manual 6
mean of previous
values
SVM
support vector
regressor (SVR)
20 sec. 0.001 sec.
Table 1: Summary of prediction methods used in the TADPOLE submissions. Keywords: SVM –
Support Vector Machine, RF – random forest, LSTM – long short-term memory network, NN – neural
network, RNN – recurrent neural network, SMNSR – Sparse Multimodal Neighbourhood Search Regres-
sion, DPM – disease progression model, KDE – kernel density estimation, LDA – linear discriminant
analysis, SM – slope model, ECOC – error-correcting output codes, SVD – singular value decomposition
(*) Augmented features, or summary statistics, such as trends, slope, min/max, moments, generally
derived patient-wise using longitudinal data. Color tags denote prediction method category: regres-
sion/proportional hazards model, random forest, neural networks, disease progression model,
machine learning (other), benchmark, other. The left-side box denotes the category for diagnosis
prediction method, while the right-side box denotes the category for ADAS/Ventricle prediction method.
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computed the performance metrics for only the submitted target variables. Another 3 submissions
lacked confidence intervals for either ADAS-Cog13 or ventricle volume, which we imputed using default
low-width confidence ranges of 2 for ADAS-Cog13 and 0.002 for Ventricles normalised by intracranial
volume (ICV).
Table 1 summarises the methods used in the submissions in terms of feature selection, handling
of missing data, predictive models for clinical diagnosis and ADAS/Ventricles biomarkers, as well as
training and prediction times. A detailed description of each method is in Online Methods Section 5.4.
In particular, some entries constructed augmented features (i.e. summary statistics), which are extra
features such as slope, min/max or moments that are derived from existing features.
In addition to the forecasts submitted by participants, we also evaluated four benchmark methods,
which were made available to participants during the submission phase of the challenge: (i) Bench-
maskLastVisit uses the measurement of each target from the last available clinical visit as the forecast,
(ii) BenchmarkMixedEffects uses a mixed effects model with age as predictor variable for ADAS and
Ventricle predictions, and Gaussian likelihood model for diagnosis prediction, (iii) BenchmarkMixedEf-
fectsAPOE is as (ii) but adds APOE status as a covariate and (iv) BenchmarkSVM uses an out-of-the-box
support vector machine (SVM) classifier and regressor (SVR) to provide forecasts. More details on these
methods can be found in Online Methods section 5.4. We also evaluated two ensemble methods based
on taking the mean (ConsensusMean) and median (ConsensusMedian) of the forecasted variables over
all submissions.
To control for potentially spurious strong performance arising from multiple comparisons, we also
evaluated 100 random predictions by adding Gaussian noise to the forecasts of the simplest benchmark
model (BenchmarkLastVisit). In the subsequent results tables we will show, for each performance metric,
only the best score obtained by any of these 100 random predictions (RandomisedBest) – See end of
Online Methods section 5.4 for more information on RandomisedBest.
2.3 Forecasts from the longitudinal prediction set (D2)
Table 2 compiles all metrics for all TADPOLE submitted forecasts, as well as benchmarks and ensemble
forecasts, from the longitudinal D2 prediction set. For details on datasets D2 and D3, see Online Methods
section 5.1, while for details on performance metrics see Online Methods section 5.2. Box-plots showing
the distribution of scores, computed on 50 bootstraps of the test set, are shown in Supplementary
Fig. C.1, while the distribution of ranks is shown in Supplementary Figs. C.8 – C.10. Among the
benchmark methods, BenchmarkMixedEffectsAPOE had the best overall rank of 18, obtaining rank 35
on clinical diagnosis prediction, rank 2 on ADAS-Cog13 and rank 23 on Ventricle volume prediction.
Removing the APOE status as covariate proved to significantly increase the predictive performance
(BenchmarkMixedEffects), although we do not show ranks for this entry as it was found during the
evaluation phase. Among participant methods, the submission with the best overall rank was Frog,
obtaining rank 1 for prediction of clinical diagnosis, rank 4 for ADAS-Cog13 and rank 10 for Ventricle
volume prediction.
For clinical diagnosis, the best submitted forecasts (team Frog) scored better than all benchmark
methods, reducing the error of the best benchmark methods by 58% for the multiclass area under
the receiver operating characteristic curve (MAUC) and by 38% for balanced classification accuracy
(BCA). Here, the best benchmarks obtained a MAUC of 0.846 (BenchmarkMixedEffects) and a BCA
of 0.792 (BenchmarkLastVisit). Among participant methods, Frog had the best MAUC score of 0.931,
significantly better than all entries other than Threedays according to the bootstrap test (p-value = 0.24,
see Supplementary section B.1 for details on significance testing). Supplementary Figure C.8 further
shows the variability in performance ranking over bootstrap samples and highlights that the top two
entries consistently remain at the top of the ranking. In terms of BCA, ARAMIS-Pascal had the best
score of 0.850. Moreover, ensemble methods (ConsensusMedian) achieved the second best MAUC score
of 0.925 and the best BCA score of 0.857. In contrast, the best randomised prediction (RandomisedBest)
achieved a much lower MAUC of 0.800 and a BCA of 0.803, suggesting entries below these scores did
not perform significantly better than random guessing according to the bootstrap test (p-value = 0.01).
MAUC and BCA performance metrics had a relatively high correlation across all submissions (r = 0.88,
Supplementary Fig. C.3).
For Ventricle volume, the best submitted forecasts among participants (team EMC1 ) also scored
considerably better than all benchmark methods, reducing the error of the best benchmark methods by
almost one third (29%) for mean absolute error (MAE) and around one half (51%) for weighted error score
(WES). Here, the best benchmark method (BenchmarkMixedEffects) had an overall Ventricle MAE and
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Overall Diagnosis ADAS-Cog13 Ventricles (% ICV)
Submission Rank Rank MAUC BCA Rank MAE WES CPA Rank MAE WES CPA
ConsensusMedian - - 0.925 0.857 - 5.12 5.01 0.28 - 0.38 0.33 0.09
Frog 1 1 0.931 0.849 4 4.85 4.74 0.44 10 0.45 0.33 0.47
ConsensusMean - - 0.920 0.835 - 3.75 3.54 0.00 - 0.48 0.45 0.13
EMC1-Std 2 8 0.898 0.811 23-24 6.05 5.40 0.45 1-2 0.41 0.29 0.43
VikingAI-Sigmoid 3 16 0.875 0.760 7 5.20 5.11 0.02 11-12 0.45 0.35 0.20
EMC1-Custom 4 11 0.892 0.798 23-24 6.05 5.40 0.45 1-2 0.41 0.29 0.43
CBIL 5 9 0.897 0.803 15 5.66 5.65 0.37 13 0.46 0.46 0.09
Apocalypse 6 7 0.902 0.827 14 5.57 5.57 0.50 20 0.52 0.52 0.50
GlassFrog-Average 7 4-6 0.902 0.825 8 5.26 5.27 0.26 29 0.68 0.60 0.33
GlassFrog-SM 8 4-6 0.902 0.825 17 5.77 5.92 0.20 21 0.52 0.33 0.20
BORREGOTECMTY 9 19 0.866 0.808 20 5.90 5.82 0.39 5 0.43 0.37 0.40
BenchmarkMixedEffects - - 0.846 0.706 - 4.19 4.19 0.31 - 0.56 0.56 0.50
EMC-EB 10 3 0.907 0.805 39 6.75 6.66 0.50 9 0.45 0.40 0.48
lmaUCL-Covariates 11-12 22 0.852 0.760 27 6.28 6.29 0.28 3 0.42 0.41 0.11
CN2L-Average 11-12 27 0.843 0.792 9 5.31 5.31 0.35 16 0.49 0.49 0.33
VikingAI-Logistic 13 20 0.865 0.754 21 6.02 5.91 0.26 11-12 0.45 0.35 0.20
lmaUCL-Std 14 21 0.859 0.781 28 6.30 6.33 0.26 4 0.42 0.41 0.09
RandomisedBest - - 0.800 0.803 - 4.52 4.52 0.27 - 0.46 0.45 0.33
CN2L-RandomForest 15-16 10 0.896 0.792 16 5.73 5.73 0.42 31 0.71 0.71 0.41
FortuneTellerFish-SuStaIn 15-16 40 0.806 0.685 3 4.81 4.81 0.21 14 0.49 0.49 0.18
CN2L-NeuralNetwork 17 41 0.783 0.717 10 5.36 5.36 0.34 7 0.44 0.44 0.27
BenchmarkMixedEffectsAPOE 18 35 0.822 0.749 2 4.75 4.75 0.36 23 0.57 0.57 0.40
Tohka-Ciszek-RandomForestLin 19 17 0.875 0.796 22 6.03 6.03 0.15 22 0.56 0.56 0.37
BGU-LSTM 20 12 0.883 0.779 25 6.09 6.12 0.39 25 0.60 0.60 0.23
DIKU-GeneralisedLog-Custom 21 13 0.878 0.790 11-12 5.40 5.40 0.26 38-39 1.05 1.05 0.05
DIKU-GeneralisedLog-Std 22 14 0.877 0.790 11-12 5.40 5.40 0.26 38-39 1.05 1.05 0.05
CyberBrains 23 34 0.823 0.747 6 5.16 5.16 0.24 26 0.62 0.62 0.12
AlgosForGood 24 24 0.847 0.810 13 5.46 5.11 0.13 30 0.69 3.31 0.19
lmaUCL-halfD1 25 26 0.845 0.753 38 6.53 6.51 0.31 6 0.44 0.42 0.13
BGU-RF 26 28 0.838 0.673 29-30 6.33 6.10 0.35 17-18 0.50 0.38 0.26
Mayo-BAI-ASU 27 52 0.691 0.624 5 4.98 4.98 0.32 19 0.52 0.52 0.40
BGU-RFFIX 28 32 0.831 0.673 29-30 6.33 6.10 0.35 17-18 0.50 0.38 0.26
FortuneTellerFish-Control 29 31 0.834 0.692 1 4.70 4.70 0.22 50 1.38 1.38 0.50
GlassFrog-LCMEM-HDR 30 4-6 0.902 0.825 31 6.34 6.21 0.47 51 1.66 1.59 0.41
SBIA 31 43 0.776 0.721 43 7.10 7.38 0.40 8 0.44 0.31 0.13
Chen-MCW-Stratify 32 23 0.848 0.783 36-37 6.48 6.24 0.23 36-37 1.01 1.00 0.11
Rocket 33 54 0.680 0.519 18 5.81 5.71 0.34 28 0.64 0.64 0.29
BenchmarkSVM 34-35 30 0.836 0.764 40 6.82 6.82 0.42 32 0.86 0.84 0.50
Chen-MCW-Std 34-35 29 0.836 0.778 36-37 6.48 6.24 0.23 36-37 1.01 1.00 0.11
DIKU-ModifiedMri-Custom 36 36-37 0.807 0.670 32-35 6.44 6.44 0.27 34-35 0.92 0.92 0.01
DIKU-ModifiedMri-Std 37 38-39 0.806 0.670 32-35 6.44 6.44 0.27 34-35 0.92 0.92 0.01
DIVE 38 51 0.708 0.568 42 7.10 7.10 0.34 15 0.49 0.49 0.13
ITESMCEM 39 53 0.680 0.657 26 6.26 6.26 0.35 33 0.92 0.92 0.43
BenchmarkLastVisit 40 44-45 0.774 0.792 41 7.05 7.05 0.45 27 0.63 0.61 0.47
Sunshine-Conservative 41 25 0.845 0.816 44-45 7.90 7.90 0.50 43-44 1.12 1.12 0.50
BravoLab 42 46 0.771 0.682 47 8.22 8.22 0.49 24 0.58 0.58 0.41
DIKU-ModifiedLog-Custom 43 36-37 0.807 0.670 32-35 6.44 6.44 0.27 47-48 1.17 1.17 0.06
DIKU-ModifiedLog-Std 44 38-39 0.806 0.670 32-35 6.44 6.44 0.27 47-48 1.17 1.17 0.06
Sunshine-Std 45 33 0.825 0.771 44-45 7.90 7.90 0.50 43-44 1.12 1.12 0.50
Billabong-UniAV45 46 49 0.720 0.616 48-49 9.22 8.82 0.29 41-42 1.09 0.99 0.45
Billabong-Uni 47 50 0.718 0.622 48-49 9.22 8.82 0.29 41-42 1.09 0.99 0.45
ATRI-Biostat-JMM 48 42 0.779 0.710 51 12.88 69.62 0.35 54 1.95 5.12 0.33
Billabong-Multi 49 56 0.541 0.556 55 27.01 19.90 0.46 40 1.07 1.07 0.45
ATRI-Biostat-MA 50 47 0.741 0.671 52 12.88 11.32 0.19 53 1.84 5.27 0.23
BIGS2 51 58 0.455 0.488 50 11.62 14.65 0.50 49 1.20 1.12 0.07
Billabong-MultiAV45 52 57 0.527 0.530 56 28.45 21.22 0.47 45 1.13 1.07 0.47
ATRI-Biostat-LTJMM 53 55 0.636 0.563 54 16.07 74.65 0.33 52 1.80 5.01 0.26
Threedays - 2 0.921 0.823 - - - - - - - -
ARAMIS-Pascal - 15 0.876 0.850 - - - - - - - -
IBM-OZ-Res - 18 0.868 0.766 - - - - 46 1.15 1.15 0.50
Orange - 44-45 0.774 0.792 - - - - - - - -
SMALLHEADS-NeuralNet - 48 0.737 0.605 53 13.87 13.87 0.41 - - - -
SMALLHEADS-LinMixedEffects - - - - 46 8.09 7.94 0.04 - - - -
Tohka-Ciszek-SMNSR - - - - 19 5.87 5.87 0.14 - - - -
Table 2: Ranked scores for all TADPOLE submissions and benchmarks using the longitudinal predic-
tion data set (D2). Best scores in each category are bolded. Missing numerical entries indicate that
submissions did not include forecasts for the corresponding target variable. The “Diagnosis” ranking
uses multiclass area under the receiver operating characteristic curve (MAUC), those of ADAS-Cog13
and Ventricles use mean absolute error (MAE). The overall ranking on the left uses the sum of the ranks
from the three target variables. The table also lists the secondary metrics: BCA – balanced classification
accuracy, WES – weighted error score, CPA – coverage probability accuracy. See Online Methods section
5.2 for details on performance metrics.
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WES of 0.56. Among participant submissions, EMC1-Std/-Custom had the best MAE of 0.41 (% ICV),
significantly lower than all entries other than lmaUCL-Covariates/-Std/-half-D1, BORREGOTECMTY
and SBIA according to the Wilcoxon signed-rank test (see Supplementary section B.2) – this is also
confirmed in Supplementary Fig. C.10 by the variability in performance ranking over bootstrap sam-
ples. Team EMC1 also had the best Ventricle WES of 0.29, while DIKU-ModifiedMri-Custom/-Std had
the best Ventricle coverage probability accuracy (CPA) of 0.01. Ensemble methods (ConsensusMean)
achieved the best Ventricle MAE of 0.38. In contrast, the best randomised prediction (RandomisedBest)
achieved a higher MAE of 0.46, WES of 0.45 and CPA of 0.33. MAE and WES scores showed high corre-
lation (r = 0.99, Supplementary Fig. C.3) and were often of equal value for many submissions (n = 24),
as teams set equal weights for all subjects analysed. CPA did not correlate (r ≈ −0.01, Supplementary
Fig. C.3) with either MAE or WES.
For ADAS-Cog13, the best submitted forecasts did not score significantly better than the simple
benchmarks. Here, the simple BenchmarkMixedEffects model obtained the second-best MAE of 4.19,
which was significantly lower than all other submitted entries according to the Wilcoxon signed-rank
test. BenchmarkMixedEffects also had the best ADAS-Cog13 WES of 4.19, while VikingAI-Sigmoid
had the best ADAS-Cog13 CPA of 0.02. Among participants’ submissions, FortuneTellerFish-Control
ranked first in ADAS-Cog13 prediction with a MAE of 4.70, which is 11% higher than the error of the
best benchmark. Moreover, all participants’ forecasts scored worse than the best randomised prediction
(RandomisedBest), which here achieved a MAE of 4.52 and WES of 4.52. Nevertheless, the ensemble
method ConsensusMean obtained the best ADAS scores for MAE (3.75), WES (3.54) and CPA (0.0),
which along with BenchmarkMixedEffects were the only entries that performed significantly better than
random guessing (p-value = 0.01). The MAE and WES scores for ADAS-Cog13 had relatively high
correlation (r = 0.97, Supplementary Fig. C.3) and were often of equal value for many submissions
(n = 25). CPA had a weak but significant correlation with MAE (r = 0.37, p-value < 0.02) and WES
(r = 0.35, p-value < 0.02).
2.4 Forecasts from the cross-sectional prediction set (D3) and custom pre-
diction sets
Table 3 shows the ranking of the forecasts from the cross-sectional D3 prediction set. Box-plots showing
the distribution of scores, computed on 50 bootstraps of the test set, are shown in Supplementary Fig
C.2, while the distribution of ranks is shown in Supplementary Figs. C.11 – C.13. Due to the lack of
longitudinal data, most submissions had lower performance compared to their equivalents from the D2
longitudinal prediction set. Among submitted forecasts, GlassFrog-Average had the best overall rank,
as well as rank 2-4 on diagnosis prediction, rank 5 on ADAS-Cog13 prediction and rank 3 on ventricle
prediction.
For clinical diagnosis prediction on D3, the best prediction among TADPOLE participants (team
IBM-OZ-Res) scored considerably better than all benchmark methods, reducing the error of the best
benchmark method by 40% for MAUC and by 25% for BCA, and achieving error rates comparable to
the best predictions from the longitudinal prediction set D2. The best benchmark methods obtained a
MAUC of 0.839 (BenchmarkMixedEffects) and a BCA of 0.771 (BenchmarkLastVisit). Among partici-
pant methods, IBM-OZ-Res had the best MAUC score of 0.905, significantly better than all entries other
than GlassFrog-SM/-Average/-LCMEM-HDR, BGU-RF/-RFFIX/-LSTM, VikingAI-Logistic, EMC-EB,
Rocket and Tohka-Ciszek-RandomForestLin according to the bootstrap hypothesis test (same method-
ology as in D2). This is further confirmed in Supplementary Fig. C.11 by the variability of ranks under
boostrap samples of the dataset, as these teams often remain at the top of the ranking. IBM-OZ-Res also
had the best BCA score of 0.830 among participants. Among ensemble methods, ConsensusMean ob-
tained the best Diagnosis MAUC of 0.917. In contrast, the best randomised prediction (RandomisedBest)
obtained an MAUC of 0.811 and a BCA of 0.783. MAUC and BCA performance metrics had a relatively
high correlation across all submissions (r = 0.9, Supplementary Fig. C.4).
For Ventricle volume prediction on D3, the best prediction (GlassFrog-LCMEM-HDR) scored consid-
erably better than all benchmark methods, reducing the error of the best benchmark methods by 58%
for MAE and 41% for WES, and achieving error rates comparable to the best predictions of D2. Here,
the best benchmark methods had an overall Ventricle MAE of 1.13 (BenchmarkMixedEffects) and WES
of 0.64 (BenchmarkLastVisit). Among participant submissions, GlassFrog-LCMEM-HDR had the best
MAE of 0.48, significantly lower than all other submitted entries according to the Wilcoxon signed-rank
test – this is also confirmed in Supplementary Fig. C.13 by the rank distribution under dataset boos-
traps. GlassFrog-LCMEM-HDR also had the best Ventricle WES of 0.38, while submissions by team
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Overall Diagnosis ADAS-Cog13 Ventricles (% ICV)
Submission Rank Rank MAUC BCA Rank MAE WES CPA Rank MAE WES CPA
ConsensusMean - - 0.917 0.821 - 4.58 4.34 0.12 - 0.73 0.72 0.09
ConsensusMedian - - 0.905 0.817 - 5.44 5.37 0.19 - 0.71 0.65 0.10
GlassFrog-Average 1 2-4 0.897 0.826 5 5.86 5.57 0.25 3 0.68 0.55 0.24
GlassFrog-LCMEM-HDR 2 2-4 0.897 0.826 9 6.57 6.56 0.34 1 0.48 0.38 0.24
GlassFrog-SM 3 2-4 0.897 0.826 4 5.77 5.77 0.19 9 0.82 0.55 0.07
Tohka-Ciszek-RandomForestLin 4 11 0.865 0.786 2 4.92 4.92 0.10 10 0.83 0.83 0.35
RandomisedBest - - 0.811 0.783 - 4.54 4.50 0.26 - 0.92 0.50 0.00
lmaUCL-Std 5-9 12-14 0.854 0.698 16-18 6.95 6.93 0.05 5-7 0.81 0.81 0.22
lmaUCL-Covariates 5-9 12-14 0.854 0.698 16-18 6.95 6.93 0.05 5-7 0.81 0.81 0.22
lmaUCL-halfD1 5-9 12-14 0.854 0.698 16-18 6.95 6.93 0.05 5-7 0.81 0.81 0.22
Rocket 5-9 10 0.865 0.771 3 5.27 5.14 0.39 23 1.06 1.06 0.27
VikingAI-Logistic 5-9 8 0.876 0.768 6 5.94 5.91 0.22 22 1.04 1.01 0.18
EMC1-Std 10 30 0.705 0.567 7 6.29 6.19 0.47 4 0.80 0.62 0.48
BenchmarkMixedEffects - - 0.839 0.728 - 4.23 4.23 0.34 - 1.13 1.13 0.50
SBIA 11 28 0.779 0.782 10 6.63 6.43 0.40 8 0.82 0.75 0.18
BGU-LSTM 12-14 5-7 0.877 0.776 13-15 6.75 6.17 0.39 26-28 1.11 0.79 0.17
BGU-RFFIX 12-14 5-7 0.877 0.776 13-15 6.75 6.17 0.39 26-28 1.11 0.79 0.17
BGU-RF 12-14 5-7 0.877 0.776 13-15 6.75 6.17 0.39 26-28 1.11 0.79 0.17
BravoLab 15 18 0.813 0.730 28 8.02 8.02 0.47 2 0.64 0.64 0.42
BORREGOTECMTY 16-17 15 0.852 0.748 8 6.44 5.86 0.46 30 1.14 1.02 0.49
CyberBrains 16-17 17 0.830 0.755 1 4.72 4.72 0.21 35 1.54 1.54 0.50
ATRI-Biostat-MA 18 19 0.799 0.772 26 7.39 6.63 0.04 11 0.93 0.97 0.10
DIKU-GeneralisedLog-Std 19-20 20 0.798 0.684 20-21 6.99 6.99 0.17 16-17 0.95 0.95 0.05
EMC-EB 19-20 9 0.869 0.765 27 7.71 7.91 0.50 21 1.03 1.07 0.49
DIKU-GeneralisedLog-Custom 21 21 0.798 0.681 20-21 6.99 6.99 0.17 16-17 0.95 0.95 0.05
DIKU-ModifiedLog-Std 22-23 22-23 0.798 0.688 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
DIKU-ModifiedMri-Std 22-23 22-23 0.798 0.688 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
DIKU-ModifiedMri-Custom 24-25 24-25 0.798 0.691 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
DIKU-ModifiedLog-Custom 24-25 24-25 0.798 0.691 22-25 7.10 7.10 0.17 12-15 0.95 0.95 0.05
Billabong-Uni 26 31 0.704 0.626 11-12 6.69 6.69 0.38 19-20 0.98 0.98 0.48
Billabong-UniAV45 27 32 0.703 0.620 11-12 6.69 6.69 0.38 19-20 0.98 0.98 0.48
ATRI-Biostat-JMM 28 26 0.794 0.781 29 8.45 8.12 0.34 18 0.97 1.45 0.37
CBIL 29 16 0.847 0.780 33 10.99 11.65 0.49 29 1.12 1.12 0.39
BenchmarkLastVisit 30 27 0.785 0.771 19 6.97 7.07 0.42 33 1.17 0.64 0.11
Billabong-MultiAV45 31 33 0.682 0.603 30-31 9.30 9.30 0.43 24-25 1.09 1.09 0.49
Billabong-Multi 32 34 0.681 0.605 30-31 9.30 9.30 0.43 24-25 1.09 1.09 0.49
ATRI-Biostat-LTJMM 33 29 0.732 0.675 34 12.74 63.98 0.37 32 1.17 1.07 0.40
BenchmarkSVM 34 36 0.494 0.490 32 10.01 10.01 0.42 31 1.15 1.18 0.50
DIVE 35 35 0.512 0.498 35 16.66 16.74 0.41 34 1.42 1.42 0.34
IBM-OZ-Res - 1 0.905 0.830 - - - - 36 1.77 1.77 0.50
Table 3: Ranked prediction scores for all TADPOLE submissions that used the cross-sectional predic-
tion data set (D3). Best scores in each category are bolded. Missing numerical entries indicate that
submissions did not include predictions for the corresponding target variable. The “Diagnosis” ranking
uses multiclass area under the receiver operating characteristic curve (MAUC), those of ADAS-Cog13
and Ventricles use mean absolute error (MAE). The overall ranking on the left uses the sum of the ranks
from the three target variables. The table also lists the secondary metrics: BCA – balanced classification
accuracy, WES – weighted error score, CPA – coverage probability accuracy.
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DIKU had the best Ventricle CPA of 0.05. Among ensemble methods, ConsensusMedian obtained a
Ventricle MAE of 0.71 (4th best) and WES of 0.65 (7th best). In contrast, the best randomised predic-
tion (RandomisedBest) obtained a Ventricle MAE of 0.92, WES of 0.50 and CPA of 0. As in D2, MAE
and WES scores in D3 for Ventricles had very high correlation (r = 0.99, Supplementary Fig. C.4),
while CPA showed weak correlation with MAE (r = 0.24, p-value = 0.17) and WES (r = 0.37, p-value
< 0.032).
For ADAS-Cog13 on D3, the predictions submitted by participants again did not perform better
than the best benchmark methods. BenchmarkMixedEffects had the best MAE of 4.23, which was
significantly lower than all entries by other challenge participants. Moreover, the MAE of 4.23 was only
marginally worse than the equivalent error (4.19) by the same model on D2. BenchmarkMixedEffects
also had the best ADAS-Cog13 WES of 4.23, while ATRI-Biostat-MA had the best ADAS-Cog13 CPA
of 0.04. Among participants’ submissions, CyberBrains ranked first in ADAS-Cog13 prediction with a
MAE of 4.72, an error 11% higher than the best benchmark. Among ensemble methods, ConsensusMean
obtained an ADAS-Cog13 MAE of 4.58, WES of 4.34, better than all participants’ entries. As in D2,
the best randomised predictions (RandomisedBest) obtained an ADAS-Cog13 MAE of 4.54 (2nd best)
and WES of 4.50 (3rd best). As in D2, MAE and WES scores for ADAS-Cog13 had high correlation (r
= 0.97, Supplementary Fig. C.4), while CPA showed weak, non-significant correlation with MAE (r =
0.34, p-value ≈ 0.052) or WES (r = 0.33, p-value ≈ 0.057).
Results on the custom prediction sets are presented in Supplementary Table C.1.
2.5 Algorithm characteristics associated with increased performance
To understand what characteristics of algorithms could have yielded higher performance, we show in
Figure 1 associations from a general linear model between predictive performance and feature selection
methods, different types of features, methods for data imputation, and methods for forecasting of target
variables. For each type of feature/method and each target variable (clinical diagnosis, ADAS-Cog13
and Ventricles), we show the distribution of estimated coefficients from a general linear model, derived
from the approximated inverse Hessian matrix at the maximum likelihood estimator (see Online Methods
section 5.3). From this analysis we removed outliers, defined as submissions with ADAS MAE higher
than 10 and Ventricle MAE higher than 1.15 (%ICV). For all plots, distributions to the right of the gray
dashed vertical line denote increased performance compared to baseline (i.e. when those characteristics
are not used).
For feature selection, Figure 1 shows that methods with manual selection of features tend to be asso-
ciated with better predictive performance in ADAS-Cog13 and Ventricles. In terms of feature types, CSF
and DTI features were generally associated with an increase in predictive performance for clinical diag-
nosis, while augmented features were associated with performance improvements for ventricle prediction.
In terms of data imputation methods, while some differences can be observed, no clear conclusions can be
drawn. In terms of prediction models, the only positive association that indicates increased performance
is in the neural networks for ventricle prediction. However, given the small number of methods tested
(<50) and the large number of degrees of freedom, these results should be interpreted with care.
3 Discussion
In this work, we presented the results of the TADPOLE Challenge. The results of the challenge provide
important insights into the current state of the field, and how well current algorithms can predict pro-
gression of AD diagnoses and markers of disease progression both from rich longitudinal data sets and,
comparatively, from sparser cross-sectional data sets typical of a clinical trial scenario. The challenge
further highlights the algorithms, features and data-handling strategies that tend to lead to improved
forecasts. In the following sections we discuss the key conclusions that we draw from our study and
highlight important limitations.
3.1 TADPOLE pushed forward performance on AD clinical diagnosis pre-
diction
When comparing to previous state-of-the-art results in the literature, the best TADPOLE methods show
similar or higher performance in AD diagnostic classification while also tackling a harder problem than
most previous studies of predicting future, rather than estimating current, classification. A comparison
of 15 studies presented by [31] reported lower performance (maximum AUC of 0.902 vs 0.931 obtained by
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Figure 1: Associations between the prediction of clinical diagnosis, ADAS-Cog13 and Ventricle vol-
ume and different strategies of (top) feature selection, (upper-middle) types of features, (lower-middle)
data imputation strategies and (bottom) prediction methods for the target variables. For each type of
feature/method (rows) and each target variable (columns), we show the distribution of estimated co-
efficients from a general linear model. Positive coefficients, where distributions lie to the right of the
dashed vertical line, indicate better performance than baseline (vertical dashed line). For ADAS-Cog13
and Ventricle prediction, we flipped the sign of the coefficients, to consistently show better performance
to the right of the vertical line.
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the best TADPOLE method) for the simpler two-class classification problem of separating MCI-stable
from MCI-converters in ADNI. A more recent method by [32] reported a maximum AUC of 0.932 and
accuracy of 0.88 at the same MCI-stable vs -converter classification task. However, a) TADPOLE’s
discrimination of CN-converters from CN-stable subjects is harder as disease signal is weaker at such
early stages, and b) the predictive performance drops in three-class problems like TADPOLE compared
to two-class. Furthermore, the best out of 19 algorithms in the CADDementia Challenge [26] obtained
an MAUC of 0.78.
We are unaware of previous studies forecasting future ventricle volume or ADAS-Cog13, so TADPOLE
sets a new benchmark state-of-the-art performance on these important prediction tasks.
3.2 No one-size-fits-all prediction algorithm
The results on the longitudinal D2 prediction set suggest no clear winner on predicting all target variables
– no single method performed well on all tasks. While Frog had the best overall submission with the lowest
sum of ranks, for each performance metric individually we had different winners: Frog (clinical diagnosis
MAUC of 0.931), ARAMIS-Pascal (clinical diagnosis BCA of 0.850), BenchmarkMixedEffects (ADAS-
Cog13 MAE and WES of 4.19), VikingAI-Sigmoid (ADAS-Cog13 CPA of 0.02), EMC1-Std/EMC1-
Custom (ventricle MAE of 0.41 and WES or 0.29), and DIKU-ModifiedMri-Std/-Custom (ventricle CPA
of 0.01). Moreover, on the cross-sectional D3 prediction set, the methods by Glass-Frog had the best
performance. Associations of method-type with increased performance in Fig. 1 confirm no clear increase
in performance for any types of prediction methods (with the exception of neural networks for ventricle
volume prediction). This raises an important future challenge to algorithm designers to develop methods
able to perform well on multiple forecasting tasks and also in situations with limited data, such as D3.
3.3 Ensemble methods perform strongly
Consistently strong results from ensemble methods (ConsensusMean/ConsensusMedian outperformed
all others on most tasks) might suggest that different methods over-estimate future measurements for all
subjects while others under-estimate them, likely due to the underlying assumptions they make. This
is confirmed by plots of the difference between true and estimated measures (Supplementary Figures
C.5–C.7), where most methods systematically under- or over-estimate in all subjects. However, even if
methods were completely unbiased, averaging over all methods could also help predictions by reducing
the variance in the estimated target variables.
3.4 Predictability of ADAS-Cog13 scores
ADAS-Cog13 scores were more difficult to forecast than clinical diagnosis or ventricle volume. The only
single method able to forecast ADAS-Cog13 better than informed random guessing (RandomisedBest)
was the BenchmarkMixedEffects, a simple mixed effects model with no covariates and age as a regres-
sor. The difficulty could be due to variability in administering the tests or practice effects. A useful
target performance level comes from the 4 points change generally used to identify responders to a drug
treatment [33]. With the exception of the ensemble method, all submitted forecasts failed to produce
mean error below 4, highlighting the substantial challenge of estimating change in ADAS-Cog13 over
the 1.4 year interval – although over longer time periods, non-trivial forecasts are likely to improve in
comparison to RandomisedBest, which is independent of time period. Nevertheless, for the longitudinal
D2 prediction set, the MAE in ADAS-Cog13 from ConsensusMean was 3.75, which restores hope in
forecasting cognitive score trajectories even over relatively short timescales.
3.5 Prediction errors from limited cross-sectional dataset mimicking clinical
trials are similar to those from longitudinal dataset
For clinical diagnosis, the best performance on the limited, cross-sectional D3 prediction set was similar
to the best performance on the D2 longitudinal prediction set: 0.917 vs 0.931 for MAUC (p-value =
0.14), representing a 3% error increase for D3 compared to D2. Slightly larger and significant differences
were observed for ADAS MAE (3.75 vs 4.23, p-value < 0.01) and Ventricle MAE (0.38 vs 0.48, p-value
< 0.01). It should be noted that Ventricle predictions for D3 were extremely difficult, given that only
25% of subjects to be forecasted had MRI data in D3. This suggests that, for clinical diagnosis, current
forecast algorithms are reasonably robust to lack of longitudinal data and missing inputs, while for ADAS
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and Ventricle volume prediction, some degree of performance is lost. Future work is also required to
determine the optimal balance of input data quality and quantity versus cost of acquisition.
3.6 DTI and CSF features appear informative for clinical diagnosis predic-
tion, augmented features appear informative for ventricle prediction
DTI and CSF features are most associated with increases in clinical diagnosis forecast performance.
CSF, in particular, is well established as an early marker of AD [34] and likely to help predictions for
early-stage subjects, while DTI, measuring microstructure damage, may be informative for middle-stage
subjects. On the other hand, for prediction of ventricle volume, augmented features had the highest
association with increases in prediction performance. Future work is required to confirm the added value
of these features and others in a more systematic way.
3.7 Challenge design and limitations
TADPOLE Challenge has several limitations that future editions of the challenge may consider address-
ing. One limitation is the reliability of the three target variables: clinical diagnosis, ADAS-Cog13 and
Ventricle volume. First of all, clinical diagnosis has only moderate agreement with gold-standard neu-
ropathological post-mortem diagnosis. In particular, one study [35] has shown that a clinical diagnosis of
probable AD has sensitivity between 70.9% and 87.3% and specificity between 44.3% and 70.8%. With
the advent of post-mortem confirmation in ADNI, future challenges might address this by evaluating the
algorithms on subjects with pathological confirmation. Similarly, ADAS-Cog13 is known to suffer from
low reliability across consecutive visits [33], and TADPOLE algorithms fail to forecast it reliably. How-
ever, this might be related to the short time-window (1.4 years), and more accurate predictions might
be possible over longer time-windows, when there is more significant cognitive decline. Ventricle volume
measurements depend on MRI scanner factors such as field strength, manufacturer and pulse sequences
[36], although these effects have been removed to some extent by ADNI through data preprocessing and
protocol harmonization. TADPOLE Challenge also assumes all subjects either remain stable or convert
to Alzheimer’s disease, whereas in practice some of them might develop other types of neurodegenerative
diseases.
For performance evaluation, we elected to use very simple yet reliable metrics as the primary per-
formance scores: the multiclass area under the curve (mAUC) for the clinical categorical variable and
the mean absolute error (MAE) for the two numerical variables. While the mAUC accounts for decision
confidence, the MAE does not, which means that the confidence intervals submitted by participants do
not contribute to the rankings computed in Tables 2 and 3. While the weighted error score (WES)
takes confidence intervals into account, we consider it susceptible to “hacking”, e.g. participants might
assign high confidence to only one or two data points and thereby skew the score to ignore most of
the predictions – in practice, we did not observe this behaviour in any submission. For clinical rele-
vance, we believe that confidence intervals are an extremely important part of such predictions and urge
future studies to consider performance metrics that require and take account of participant-calculated
confidence measures.
TADPOLE has other limitations related to the algorithms’ comparability and generalisability. First
of all, the evaluation and training were both done on data collected by ADNI – in future work, we plan
to assess how the models will generalise on different datasets. Another limitation is that we can only
compare full methods submissions and not different types of features, and strategies for data imputation
and prediction used within the full method. While we tried to evaluate the effect of these characteristics in
Figure 1, in practice the numbers were small and hence most effects did not reach statistical significance.
Moreover, the challenge format does not provide an exhaustive comparison of all combinations of data
processing, predictive model, features, etc., so does not lead to firm conclusions on the best combinations
but rather provides hypotheses for future testing. In future work, we plan to test inclusion of features
and strategies for data imputation and prediction independently, by changing one such characteristic at
a time.
Another limitation is that the number of controls and MCI converters in the D4 test set is low (9 MCI
converters and 9 control converters). However, these numbers will increase over time as ADNI acquires
more data, and we plan to re-run the evaluation at a later stage with the additional data acquired after
April 2019. A subsequent evaluation will also enable us to evaluate the TADPOLE methods on longer
time-horizons, over which the effects of putative drugs would be higher.
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4 Conclusion
In this work we presented the results of the TADPOLE Challenge. The results of the challenge provide im-
portant insights into the current state of the art in AD forecasting, such as performance levels achievable
with current data and technology as well as specific algorithms, features and data-handling strategies that
support the best forecasts. The developments and outcomes of TADPOLE Challenge can aid refinement
of cohorts and endpoint assessment for clinical trials, and can support accurate prognostic information
in clinical settings. The challenge website (https://tadpole.grand-challenge.org) will stay open for
submissions, which can be added to our current ranking. The open test set remains available on the
ADNI LONI website and also allows individual participants to evaluate future submissions. Through
TADPOLE-SHARE https://tadpole-share.github.io/, we further plan to implement many TAD-
POLE methods in a common framework, to be made publicly available. TADPOLE provides a standard
benchmark for evaluation of future AD prediction algorithms.
5 Online Methods – Challenge design and prediction algorithms
5.1 Data
The challenge uses data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [28]. Specifically,
the TADPOLE Challenge made four key data sets available to the challenge participants:
• D1: The TADPOLE standard training set draws on longitudinal data from the entire ADNI history.
The data set contains measurements for every individual that has provided data to ADNI in at
least two separate visits (different dates) across three phases of the study: ADNI1, ADNI GO, and
ADNI2.
• D2: The TADPOLE longitudinal prediction set contains as much available data as we could
gather from the ADNI rollover individuals for whom challenge participants are asked to provide
predictions. D2 includes data from all available time-points for these individuals. It defines the set
of individuals for which participants are required to provide forecasts.
• D3: The TADPOLE cross-sectional prediction set contains a single (most recent) time point and a
limited set of variables from each rollover individual in D2. Although we expect worse predictions
from this data set than D2, D3 represents the information typically available when selecting a
cohort for a clinical trial.
• D4: The TADPOLE test set contains visits from ADNI rollover subjects that occurred after 1
Jan 2018 and contain at least one of the three outcome measures: diagnostic status, ADAS-Cog13
score, or ventricle volume.
While participants were free to use any training datasets they wished, we provided the D1-D3 datasets
in order to remove the need for participants to pre-process the data themselves, and also to be able to
evaluate the performance of different algorithms on the same standardised datasets. Participants that
used custom training data sets were asked also to submit results using the standard training data sets
to enable direct performance comparison. We also included the D3 cross-sectional prediction set in
order to simulate a clinical trial scenario. For information on how we created the D1-D4 datasets, see
Supplementary section A. The software code used to generate the standard datasets is openly available
on Github: https://github.com/noxtoby/TADPOLE.
Table 4 shows the demographic breakdown of each TADPOLE data set as well as the proportion of
biomarker data available in each dataset. Many entries are missing data, especially for certain biomarkers
derived from exams performed on only subsets of subjects, such as tau imaging (AV1451). D1 and D2
also included demographic data typically available in ADNI (e.g. education, marital status) as well as
standard genetic markers (e.g. Alipoprotein E – APOE epsilon 4 status).
5.2 Forecast Evaluation
For evaluation of clinical status predictions, we used similar metrics to those that proved effective in the
CADDementia challenge [26]: (i) the multiclass area under the receiver operating characteristic curve
(MAUC) and (ii) the overall balanced classification accuracy (BCA). For ADAS-Cog13 and ventricle
volume, we used three metrics: (i) mean absolute error (MAE), weighted error score (WES) and coverage
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Demographics
D1 D2 D3 D4
Overall number of subjects 1667 896 896 219
Controls†
Number (% all subjects) 508 (30.5%) 369 (41.2%) 299 (33.4%) 94 (42.9%)
Visits per subject 8.3 ± 4.5 8.5 ± 4.9 1.0 ± 0.0 1.0 ± 0.2
Age 74.3 ± 5.8 73.6 ± 5.7 72.3 ± 6.2 78.4 ± 7.0
Gender (% male) 48.6% 47.2% 43.5% 47.9%
MMSE 29.1 ± 1.1 29.0 ± 1.2 28.9 ± 1.4 29.1 ± 1.1
Converters* 18 9 - -
MCI†
Number (% all subjects) 841 (50.4%) 458 (51.1%) 269 (30.0%) 90 (41.1%)
Visits per subject 8.2 ± 3.7 9.1 ± 3.6 1.0 ± 0.0 1.1 ± 0.3
Age 73.0 ± 7.5 71.6 ± 7.2 71.9 ± 7.1 79.4 ± 7.0
Gender (% male) 59.3% 56.3% 58.0% 64.4%
MMSE 27.6 ± 1.8 28.0 ± 1.7 27.6 ± 2.2 28.1 ± 2.1
Converters* 117 37 - 9
AD†
Number (% all subjects) 318 (19.1%) 69 (7.7%) 136 (15.2%) 29 (13.2%)
Visits per subject 4.9 ± 1.6 5.2 ± 2.6 1.0 ± 0.0 1.1 ± 0.3
Age 74.8 ± 7.7 75.1 ± 8.4 72.8 ± 7.1 82.2 ± 7.6
Gender (% male) 55.3% 68.1% 55.9% 51.7%
MMSE 23.3 ± 2.0 23.1 ± 2.0 20.5 ± 5.9 19.4 ± 7.2
Converters* - - - 9
Number of clinical visits for all subjects with data available (% of total visits)
D1 D2 D3 D4
Cognitive 8862 (69.9%) 5218 (68.1%) 753 (84.0%) 223 (95.3%)
MRI 7884 (62.2%) 4497 (58.7%) 224 (25.0%) 150 (64.1%)
FDG-PET 2119 (16.7%) 1544 (20.2%) - -
AV45 2098 (16.6%) 1758 (23.0%) - -
AV1451 89 (0.7%) 89 (1.2%) - -
DTI 779 (6.1%) 636 (8.3%) - -
CSF 2347 (18.5%) 1458 (19.0%) - -
Table 4: Summary of TADPOLE datasets D1-D4. (†) Diagnosis at first visit with available data. For
D3 and D4, 192 and 6 subjects respectively did not have a diagnosis at any clinical visit, so numbers
don’t add up to 100%. (*) For D4, converters are ADNI3 subjects who are MCI, but were previously
CN, or who are AD, but were previously CN or MCI in their last visit in ADNI2. For D1, D2 and
D3, converters are CN or MCI at their earliest available visit, who progress to a later classification of
MCI/AD within 1.4 years (same duration as D4)
.
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Formula Definitions
mAUC =
1
L(L−1)
∑L
i=2
∑i
j=1 Aˆ(ci|cj) + Aˆ(cj |ci)
where Aˆ(ci|cj) = Si−ni(ni+1)/2ninj
ni, nj – number of points from class i and j. Sij –
the sum of the ranks of the class i test points, after
ranking all the class i and j data points in increasing
likelihood of belonging to class i. L – number of
classes. ci – class i.
BCA = 12L
∑L
i=1
[
TPi
TPi+FNi
+ TNiTNi+FPi
] TPi, FPi, TNi, FNi the number of true positives,
false positives, true negatives and false negatives for
class i. L number of classes
MAE = 1N
∑N
i=1
∣∣∣M˜i −Mi∣∣∣ Mi is the actual value in individual i in future data.M˜i is the participant’s best guess at Mi and N is the
number of data points
WES =
∑N
i=1 C˜i|M˜i−Mi|∑N
i=1 C˜i
Mi, M˜i and N defined as above. C˜i = (C+ − C−)−1,
where [C−, C+] is the 50% confidence interval
CPA = |ACP − 0.5|
actual coverage probability (ACP) - the proportion of
measurements that fall within the 50% confidence
interval.
Table 5: TADPOLE performance metric formulas and definitions for the terms.
probability accuracy (CPA). BCA and MAE focus purely on prediction accuracy ignoring confidence,
MAUC and WES account for accuracy and confidence, while CPA assesses the confidence interval only.
The formulas for each performance metric are summarised in Table 5. See the TADPOLE white paper
[30] for further rationale for choosing these performance metrics. In order to characterise the distribution
of these metric scores, we compute scores based on 50 bootstraps with replacement on the test dataset.
5.3 Statistical Analysis of Method Attributes with Performance
To identify which features and types of algorithms enable good predictions, we annotated each TADPOLE
submission with a set of 21 attributes related to (i) feature selection (manual/automatic and large
vs. small number of features), (ii) feature types (e.g. “uses Amyloid PET”), (iii) strategy for data
imputation (e.g. “patient-wise forward-fill”) and (iv) prediction method (e.g. “neural network”) for
clinical diagnosis and ADAS/Ventricles separately. To understand which of these annotations were
associated with increased performance, we applied a general linear model [37], Y = Xβ + , where Y is
the performance metric (e.g. diagnosis MAUC), X is the nr submissions x 21 design matrix of binary
annotations, and β show the contributions of each of the 21 attributes towards achieving the performance
measure Y .
5.4 Prediction Algorithms
Team: AlgosForGood (Members: Tina Toni, Marcin Salaterski, Veronika Lunina, Institution: N/A)
Feature selection: Manual + Automatic: Manual selection of uncorrelated variables from correlation
matrix and automatic selection of variables that have highest cumulative hazard rates in survival regres-
sion from MCI to AD.
Selected features: Demographics (age, education, gender, race, marital status), cognitive tests (ADAS-
Cog13, RAVLT immediate, RAVLT forgetting, CDRSOB, ADAS11, FDG), Ventricles, AV45, ICV,
APOE4.
Missing data: Fill-in using last available value from corresponding patient
Confounder correction: none
Method category: Statistical Regression / Proportional hazards model
Prediction method:
• Diagnosis: Aalen additive regression constructing a cumulative hazard rate for progressing to AD.
• ADAS-Cog13: regression using change in ventricles/ICV as predictive variable, stratified by last
known diagnosis.
• Ventricles: regression over month, with several pre-processing steps: 1. Enforced monotonicity by
accumulating maximum value, 2. For APOE positive patients used only last three visits due to
non-linearity 3. Stratified by diagnosis
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Team: Apocalypse (Members: Manon Ansart, Stanley Durrleman, Institution: Institut du Cerveau
et de la Moelle e´pinie`re, ICM, Paris, France)
Feature selection: Manual – important features were identified by looking at the correlations with
the diagnosis. Personal knowledge of the disease was also used to complement those results and select
relevant features. Different feature sets were compared using cross-validation.
Selected features: Cognitive features (ADAS-Cog13, MMSE, RAVLT immediate, FAQ, CDRSOB),
MRI features (WholeBrain, Entorhinal, Fusiform, MidTemp, Ventricles, Entorhinal, Hippocampus),
APOE4, education, age, clinical diagnosis
Missing data: Filled in using the mean feature value
Confounder correction: none
Method category: Machine learning / Regression
Prediction method: Linear regression is used to first predict the future of a set of features (MMSE,
ADAS-Cog13, CDRSOB, RAVLT, Ventricles) at the prediction dates. Afterwards, an SVM is used to
predict the current diagnosis for each prediction date, based on the forecasted features as well as other
features which are constant for the subject (APOE4, education, age at last known visit).
Team: ARAMIS-Pascal (Members: Pascal Lu, Institution: Institut du Cerveau et de la
Moelle e´pinie`re, ICM, Paris, France)
Feature selection: Manual, based on known biomarkers from the literature.
Selected features: APOE4, cognitive tests (CDRSB, ADAS11, ADAS-Cog13, MMSE, RAVLT
immediate, FAQ), volumetric MRI (hippocampus, ventricles, whole brain, entorhinal, fusiform, middle
temporal, ICV), whole brain FDG, CSF biomarkers (amyloid-beta, tau, phosphorylated tau), education
and age.
Missing data: Imputed using the average biomarker values across the population.
Confounder correction: none
Method category: Statistical Regression / Proportional hazards model
Prediction method: For diagnosis prediction, the Aalen model for survival analysis was used to
predict the conversion from MCI to AD, which returns the probability of a subject remaining MCI as a
function of time. The method assumes cognitively normal and dementia subjects will not convert and
thus will remain constant. The method did not predict ADAS-Cog13 or Ventricles.
Publication link: https://hal.inria.fr/tel-02433613/document
Team: ATRI Biostat (Members: Samuel Iddi1,2, Dan Li1, Wesley K. Thompson3 and Michael
C. Donohue1. Institutions: 1Alzheimer’s Therapeutic Research Institute, USC, USA; 2Department of
Statistics and Actuarial Science, University of Ghana, Ghana; 3Department of Family Medicine and
Public Health, University of California, USA)
Feature selection: Automatic - features were ranked by their importance in classifying diagnostic sta-
tus using a random forest algorithm. All cognitive tests, imaging biomarkers, demographic information
and APOE status were considered as potential features
Selected features: ADAS-Cog13, EcogTotal, CDRSOB, FAQ, MOCA, MMSE, RAVLT immediate,
Ventricles/ICV, Entorhinal, Hippocampus/ICV and FDG Pet. Age, gender and APOE status were
included as covariates. The interaction between diagnosis at first available visit and years since first
visit was also considered.
Missing data: Imputed using the MissForest Algorithm, based on a non-parametric random forest
methodology [38]. The algorithm was chosen based on its ability to handle mixed-type outcomes,
complex interactions and non-linear relationships between variables.
Confounder correction: APOE status, last known clinical status, age and gender.
Method category: Machine learning and data-driven disease progression models
Prediction method: The method applied different types of mixed-effects models to forecast ADAS-
Cog13 and Ventricles, and then used a Random Forest classifier to predict the clinical diagnosis from
the forecasted continuous scores.
• JMM – Joint Mixed-effect Modelling with subject-specific intercept and slope.
• LTJMM – Latent Time Joint Mixed-effect Modelling with subject-specific intercept, slope and
time-shift
• MA – Model average of the two models above, as well as a third model where random intercepts
are shared across outcomes.
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Confidence Intervals: The 50% prediction intervals for ADAS-Cog13 and Ventricles were obtained
by taking the 25th and 75th percentile of the posterior predicted samples.
Publication link: https://braininformatics.springeropen.com/articles/10.1186/
s40708-019-0099-0
Team: BGU (Members: Aviv Nahon, Yarden Levy, Dan Halbersberg, Mariya Cohen, Institu-
tion: Ben Gurion University of the Negev, Beersheba, Israel)
Feature selection: Automatic – used the following algorithm: 1. Find the two variables with highest
correlation (Spearman for continuous variables and Mutual information for discrete variables). 2.
Compute the correlation of each variable with the target variables separately and remove the variable
with the lower correlation. 3. If there are still pairs of variables with a correlation of more than 80%,
repeat from step 1.
Selected features: Cognitive tests (CDRSOB, MMSE, RAVLT, MOCA, all Ecog), MRI biomarkers
(Freesurfer cross-sectional and longitudinal), FDG- PET (hypometabolic convergence index), AV45
PET (Ventricles, Corpus Callosum, Hippocampus), White-matter hypointensities’ volume, CSF
biomarkers (amyloid-beta, tau, phosphorylated tau). For each continuous variable, an additional set
of 20 augmented features was used, representing changes and trends in variables (e.g. mean, standard
deviation, trend mean, trend standard deviation, minimum, mean minus global mean, baseline value,
last observed value). This resulted in 233 features, which were used for prediction.
Missing data: Random forest can deal automatically with missing data. LSTM network used indicator
that was set to zero for missing data.
Confounder correction: None
Method category: Machine learning
Prediction method:
• BGU-LSTM : This model consisted of two integrated neural networks: an LSTM network for
modelling continuous variables and a feed-forward neural network for the static variables.
• BGU-RF : A semi-temporal Random Forest was used which contained the augmented features.
• BGU-RFFIX : Same as BGU-RF, but with small correction for the prediction of diagnosis:
whenever the model predicted AD with probability higher than 80%, the probability of CN was
changed to zero and vice versa.
Team: BIGS2 (Members: Huiling Liao, Tengfei Li, Kaixian Yu, Hongtu Zhu, Yue Wang, Binxin
Zhao, Institution: University of Texas, Houston, USA)
Feature selection: Automatic – used auto-encoder to extract aggregated features.
Selected features: All continuous features in D1/D2, which represented the input for the autoencoder.
Apart from the autoencoder-extracted features, other features used for the classifier were demographic
information, APOE status, whole brain biomarkers from MRI (volume) and PET (FDG, PIB and
AV45), and MMSE.
Missing data: SoftImpute method [39] was used for imputing missing data. The complete dataset was
then used as input to the autoencoder.
Confounder correction: none
Method category: Regression and Machine Learning
Prediction method: Linear models were used to predict ADAS-Cog13 and Ventricle scores indepen-
dently. For prediction of clinical diagnosis, a random forest was used based on the autoencoder-extracted
features and the other selected features.
Team: Billabong (Members: Neil Oxtoby, Institution: University College London, UK)
Feature selection: Manual, using knowledge from literature
Selected features: MRI biomarkers normalised by ICV (ventricles, hippocampus, whole brain, en-
torhinal, fusiform, middle temporal), FDG, AV45, CSF biomarkers (amyloid beta, tau, phosphorylated
tau) and cognitive tests (ADAS-Cog13, MMSE, MOCA, RAVLT immediate). Separate submissions
(Billabong-UniAV45, Billabong-MultiAV45) were made which also included AV45, that was initially
excluded due to noise.
Missing data: Only imputed during staging via linear regression against age. The method can deal
with missing data during training.
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Confounder correction: None
Method category: Data-driven disease progression model
Prediction method: For each selected feature independently, a data-driven longitudinal trajectory
was estimated using a differential equation model based on Gaussian Process Regression [14]. Subjects
were staged using either a multivariate or univariate approach:
• Billabong-Uni: Univariate staging which estimates disease stage for each target variable indepen-
dently.
• Billabong-Multi: Multivariate staging that combines all selected features, producing an average
disease stage.
For the prediction of clinical diagnosis, the historical ADNI diagnoses were mapped to a linear scale
using partially-overlapping squared-exponential distribution functions. The linear scale and the three
distributions were used to forecast the future diagnoses.
Custom prediction set: Predictions were made also for a custom dataset, which was similar to D3 but
missing data was filled in using the last available biomarker data.
Confidence Intervals: The 25th and 75th percentiles of the GPR posterior were each integrated
into a trajectory to obtain 50% confidence (credible) intervals for the forecasts of ADAS-Cog13 and
Ventricles/ICV.
Publication link: https://doi.org/10.1093/brain/awy050
Team: BORREGOSTECMTY (Members: Jos Gerardo Tamez-Pea, Institution: Tecnologico
de Monterrey, Monterrey, Mexico)
Feature selection: Automatic, using bootstrapped stage-wise selection.
Selected features: Main cognitive tests (excluding subtypes), MRI biomarkers, APOE status,
demographic information (age, gender, education) and diagnosis status. Augmented features were
further constructed from the MRI set: the cubic root of all volumes, the square root of all surface areas,
the compactness, the coefficient of variation, as well as the mean value and absolute difference between
the left and right measurements.
Missing data: Imputed using nearest-neighbourhood strategy based on L1 norm.
Confounder correction: Gender and intracranial volume (ICV) adjustments relative to controls.
Method category: Regression (ensemble of statistical models)
Prediction method: ADAS-Cog13 and Ventricles were predicted using an ensemble of 50 linear
regression models, one set for each diagnostic category. The best models were selected using Bootstrap
Stage-Wise Model Selection, using statistical fitness [40] tests to evaluate models and features to use
within the models. All selected models were then averaged in a final prediction using bagging. For
prediction, the last known diagnosis of the subject was used to select the category of models for
forecasting.
For the prediction of clinical diagnosis, a two-stage approach was used based on prognosis and
time-to-event estimation. The prognosis approach used an ensemble of 50 regression models to estimate
the future diagnosis, while the time-to-event method used an ensemble of 25 models to estimate the
square root of the time it took for a subject to convert to MCI or AD. These approaches were performed
independently for CN-to-MCI, MCI-to-AD and CN-to-AD conversion.
Confidence Intervals: The 50% confidence intervals for ADAS-Cog13 and Ventricle volume were
estimated by extracting the interquartile range of the 50 regression estimates.
Repository link: https://github.com/joseTamezPena/TADPOLE
Team: BravoLab (Members: Aya Ismail, Timothy Wood, Hector Corrada Bravo, Institu-
tion: University of Maryland, USA)
Feature selection: Automatic, using a random forest to select features with highest cross-entropy or
GINI impurity reduction.
Selected features:
• Ventricle prediction: MRI volumes of ventricular sub-regions (Freesurfer cross-sectional and longi-
tudinal)
• ADAS-Cog13 prediction: RAVLT, Diagnosis, MMSE, CDRSOB
• Diagnosis prediction: ADAS-Cog13, ADAS11, MMSE, CSRSOB
Missing data: Imputation using Hot Deck [41] was done only for data missing at random.
Confounder correction: None
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Method category: Machine learning
Prediction method: A long-short term memory network (LSTM) with target replication was trained
independently for each category: Diagnosis, ADA13 and Ventricles. All existing data was used for the
first forecast, after which the output of the last prediction was used as input for the next prediction,
along with other features that remain constant over time. Since subjects had a different number of
visits and available biomarker data, the network was adapted to accept inputs of variable length. For
predictions, the network used a weighted mean absolute error as a loss function. In addition, for the
prediction of the clinical diagnosis, a soft-max function was used to get the final prediction.
Team: CBIL (Members: Minh Nguyen, Nanbo Sun, Jiashi Feng, Thomas Yeo, Institution:
National University of Singapore, Singapore)
Feature selection: Manual, based on model performance on D1 subset.
Selected features: Cognitive tests (CDRSOB, ADAS11, ADAS-Cog13, MMSE, RAVLT immediate,
learning, forgetting and percent forgetting, MOCA, FAQ), MRI biomarkers (entorhinal, fusiform,
hippocampus, ICV, middle temporal, ventricles, whole brain), whole brain AV45 and FDG, CSF
biomarkers (amyloid-beta, tau, phosphorylated tau).
Missing data: Imputation using interpolation.
Confounder correction: None
Method category: Machine learning and data-driven disease progression model
Prediction method: Recurrent neural network adapted for variable duration between time-points.
A special loss function was designed, which ensured forecasts at timepoints close together are more
correlated than those at timepoints further apart.
Confidence Intervals: hardcoded values
Publication link: https://www.biorxiv.org/content/10.1101/755058v1
Repository link: https://github.com/ThomasYeoLab/CBIG/tree/master/stable_projects/
predict_phenotypes/Nguyen2020_RNNAD
Team: Chen-MCW (Members: Gang Chen, Institution: Medical College of Wisconsin, Mil-
waukee, USA)
Feature selection: Manual
Selected features: ADAS-Cog13, MMSE, MRI volumes (hippocampus, whole brain, entorhinal,
fusiform and middle temporal), APOE status, gender and education.
Missing data: No imputation performed.
Confounder correction: None
Method category: Regression and data-driven disease progression model
Prediction method: Prediction of ADAS-Cog13 and Ventricles was made using linear regression using
age, APOE status, gender and education as covariates. Different models were estimated for CN, MCI
and AD subjects. For diagnosis prediction, an AD risk stage was calculated based on the Event-based
probability (EBP) model [42]. Prediction of clinical diagnosis was then made based on two approaches:
• Chen-MCW-Std: Predict diagnosis based on AD stage as well as APOE4, gender and education
using a Cox proportional hazards model.
• Chen-MCW-Stratify: As above, but the model was further stratified based on AD risk stages, into
low risk and high-risk.
Team: CN2L (Members: Ke Qi1, Shiyang Chen1,2, Deqiang Qiu1,2, Institutions: 1Emory University,
2Georgia Institute of Technology)
Feature selection: Automatic
Selected features: For the neural network, all features in D1/D2 are used; For the random forest, the
main cognitive tests, MRI biomarkers (cross-sectional only), FDG, AV45, AV1451, DTI, CSF, APOE,
demographics and clinical diagnosis are used.
Missing data: Imputation in a forward filled manner (i.e. using last available value).
Confounder correction: None
Method category: Machine learning
Prediction method:
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• CN2L-NeuralNetwork : 3-layer recurrent neural network, 1024 units/layer. Dropout layers
(dropout rate:0.1) were added to output and state connections to prevent overfitting. Adam method
was used for training. Validation was performed using a leave-last-time-point-out approach.
• CN2L-RandomForest : Random forest method was used, where features of small importance
for diagnosis prediction were filtered out. For the prediction of clinical diagnosis, an ensemble of
200 trees was trained on a class-balanced bootstrap sample of the training set. For the prediction
of ADAS-Cog13 and Ventricles, an ensemble of 100 trees was used. Different predictions are made
for different previous visits of a patient, and the final prediction is taken as the average of all
predictions.
• CN2L-Average : The average of the above two methods.
Confidence Intervals: Confidence intervals are estimated based on probabilities output of the model.
Publication link: https://cds.ismrm.org/protected/18MPresentations/abstracts/3668.html
Chen et al., ISMRM, 2018 [43]
Team: CyberBrains (Members: Ionut Buciuman, Alex Kelner, Raluca Pop, Denisa Rimo-
cea, Kruk Zsolt, Institution: Vasile Lucaciu College, Baia Mare, Romania)
Feature selection: Manual
Selected features: MRI volumes (Ventricles, middle temporal), ADAS-Cog13, APOE status
Missing data: For subjects with no ventricle measurements, authors computed an average value based
on ADAS-Cog13 tests. This was used especially for D3 predictions.
Confounder correction: None
Method category: Regression
Prediction method: Fit a linear model of monthly difference in ventricle volume, as a function of
ventricle volume, stratified by clinical diagnosis and ventricle volumes smaller and larger than 140,000
mm3. A similar model is applied for ADAS-Cog13 prediction, but stratified by APOE status and middle
temporal volume smaller or greater than 16,000 mm3. Prediction of clinical diagnosis also used a linear
model that was stratified based on the ADAS-Cog13, for ADAS-Cog13 ranges between 10 and 45. For
ADAS-Cog13 greater than 45 and smaller than 10, pre-defined values were used for the probabilities of
each diagnosis.
Team: DIKU (Members: Mostafa Mehdipour Ghazi1,2,3,5, Mads Nielsen1,2,3, Akshay Pai1,2,3, Marc
Modat4,5, M. Jorge Cardoso4,5, Sebastien Ourselin4,5, Lauge Sørensen1,2,3; Institutions: 1Biomediq
A/S, 2Cerebriu A/S, 3University of Copenhagen, Denmark, 4King’s College London, UK, 5University
College London, UK)
Feature selection: Semi-automatic; linear discriminant analysis (LDA) was applied to select the top
most-informative biomarkers, and ventricular volume and a few other MRI measures were subsequently
manually added.
Selected features: Cognitive tests (CDR-SB, ADAS-11, ADAS-13, MMSE, FAQ, MOCA, RAVLT-
Immediate, RAVLT-Learning, RAVLT-Percent-Forgetting), CSF measures (amyloid-beta, phosphory-
lated tau), MRI volumetric measures divided by ICV (ventricles, hippocampus, whole brain, entorhinal,
fusiform, middle temporal).
Missing data: Method automatically deals with missing data.
Confounder correction: Linear transformation of age as part of the algorithm.
Method category: Data-driven disease progression model.
Prediction method: For predicting ADAS-13 and Ventricles, a data-driven disease progression model
was used, which estimated a parametric trajectory for each selected feature over a common disease
progression axis reflecting an estimated latent disease progression score (DPS). The chosen parametric
function was generalised logistic function (Richard’s curve), and the DPS was a linear transformation of
the age of subjects representing the subject-specific time shift and progression speed. The constrained
fitting was performed alternating between estimation of subject-specific DPS transformations and global
biomarker trajectories using L2-norm loss functions. The authors made three submissions:
• DIKU-GeneralisedLog-Std: constrained, generalised logistic function for the trajectory model;
• DIKU-ModifiedLog-Std: constrained sigmoid function for the trajectory model;
• DIKU-ModifiedMri-Std: as above, but separately fitting MRI biomarkers for Ventricles prediction.
The above models were trained on D1 data only. Authors also made predictions from a custom training
set (D1+D2 together), named DIKU-***-Custom. Clinical diagnosis was predicted based on the DPS
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scores using both a Bayesian classifier with likelihoods modeling using Gaussian mixture models, as
well as an ensemble of LDAs. The final prediction was obtained through bagging of the two classifiers’
predictions. The whole method and a robust extension developed post-TADPOLE is described in [44].
Confidence Intervals: They were obtained by using bootstrapping via Monte Carlo resampling and
evaluating the model performance assuming a Gaussian distribution.
Publication link: https://arxiv.org/abs/1908.05338
Team: DIVE (Members: Razvan Marinescu, Institution: University College London, UK,
Massachusetts Institute of Technology, USA)
Feature selection: Manual
Selected features: FDG, AV45, CDRSOB, ADAS-Cog13, MRI volumes (ventricles, hippocampus,
whole brain, entorhinal, middle temporal), CSF (amyloid-beta, tau, phosphorylated tau)
Missing data: Method automatically deals with missing data
Confounder correction: None
Method category: Data-driven disease progression model
Prediction method:
For predicting the ADAS-Cog13 and Ventricle volume, the Data-Driven Inference of Vertexwise
Evolution (DIVE) algorithm was used [17], which clusters the input biomarkers based on how similar
their progression is over the disease time-course. While the original DIVE method was a spatio-temporal
model, for TADPOLE it was applied on extracted features directly. The model estimates a parametric,
sigmoidal trajectory of the biomarkers, which are a function of subjects’ disease progression scores
(DPS), representing a linear transformation of their age. Subject-specific parameters included the latent
time-shift and progression speed, as well as an intercept. For the prediction of clinical diagnosis, the
posterior probability of each class was computed given the future DPS scores using non-parametric
Kernel Density Estimators (KDE), fitted on the DPS scores for each diagnostic class independently.
Code for the model is available online:
Confidence Intervals: The model estimates a variance parameter under a gaussian noise model, which
was scaled accordingly to obtain the 50% confidence intervals for ADAS-Cog13 and Ventricle volume.
Publication link: https://www.sciencedirect.com/science/article/pii/S1053811919301491
Repository link: https://github.com/mrazvan22/dive
Team: EMC1 (Members: Vikram Venkatraghavan, Esther Bron, Stefan Klein, Institution:
Erasmus MC, The Netherlands)
Feature selection: Automatic – Only the subjects who had converted to AD were used for feature
selection. Features with the largest changes over time after correcting for age, gender, education and
ICV were selected
Selected features: 250 features from the set of FDG, AV45, DTI, MRI (cross-sectional Freesurfer
volumes), Arterial Spin Labelling (ASL) MRI, CSF and cognitive tests.
Missing data: Imputed using nearest-neighbour interpolation. For D2, visits with missing diagnosis
were excluded. For the D3 subjects with no known diagnosis, this was estimated using a nearest-
neighbour search based on disease severity
Confounder correction: Corrected for age, gender, education and ICV using linear regression based
on data from controls.
Method category: Data-driven disease progression model and machine learning
Prediction method: Authors hypothesize that aging and progression of AD are the primary causes for
the change in biomarker values with time and that these changes eventually lead to a change in clinical
status. To predict biomarker values at future timepoints, the rate of AD progression is estimated in each
subject. This is followed by estimating the interactions of aging and AD progression in the progression
of different biomarkers. Lastly, authors use the biomarkers estimated at the future timepoint to predict
the change in clinical status. These steps are elaborated below:
Rate of Progression of AD: To assess the severity of AD, we estimated the sequence in which the
selected features became abnormal in AD using a Discriminative Event-Based Model [45] and used it
to estimate the disease severity at all the timepoints for each subject. A linear mixed effect model was
fit to estimate the rate of change of disease severity for different subjects. This model was used for
predicting the disease severity at all the future timepoints.
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Interactions of aging and AD progression: For predicting the biomarker values at the future timepoint,
we fit linear mixed effect models for each biomarker considering interactions between the estimated
disease severity and age, with gender and ICV as additional covariates. This model was used to forecast
the future values of all 250 selected features, including ADAS-Cog13 scores and Ventricle volumes.
Predicting the change in clinical status: For the diagnosis prediction, the forecasted values of the
biomarkers and the last known clinical diagnosis of the subject were used as inputs for a soft-margin
SVM classifier with a radial basis function kernel. Two separate submissions were made:
• EMC1-Std (ID 1): ASL based features were excluded in this model
• EMC1-Custom (ID 2): ASL based features were included in this model
Confidence Intervals: Standard errors of the predicted values of Ventricles and ADAS-Cog-13 were
estimated by repeating the prediction procedure, including the estimation of disease severity, for 10
repetitions of bootstrap sampling. These standard errors were used to define the confidence intervals.
Publication link: https://doi.org/10.1016/j.neuroimage.2018.11.024
Repository link: https://github.com/88vikram/TADPOLE_submission_with_debm
Team: EMC-EB (Members: Esther E. Bron, Vikram Venkatraghavan, Stefan Klein, Insti-
tution: Erasmus MC, The Netherlands)
Feature selection: Automatic – For the D2 prediction, features were selected that had the largest
change over time in subjects who converted to AD using corrections for age, gender, education and ICV,
i.e. the same approach as EMC1. For the D3 prediction, features with less than 50% missing data were
selected.
Selected features: 200 (D2 prediction) and 338 (D3 prediction) from the set of clinical diagnosis,
cognitive tests, MRI volumes (Freesurfer cross-sectional), FDG PET, DTI measures (FA, MD, RD, AD)
and CSF features.
Missing data: Imputation using nearest-neighbour interpolation based on the subject’s earlier
timepoints. If not possible, imputation by the mean of training set was used. Visits with no clinical
diagnosis were excluded for classifier training.
Confounder correction: None
Method category: Machine learning
Prediction method: All predictions were based on SVMs. For diagnosis and ADAS-Cog13 prediction,
respectively a classifier with balanced class weights and a regressor were trained to predict the target
measures at the next visit. These predictions do not explicitly take account of time, but assume that the
times between two visits are roughly equal. For Ventricle prediction, a regressor was trained to predict
the change of ventricle volume per year. Ventricle volumes were normalized using ICV at baseline (ICV
at current time point for D3). Using the predicted change, the normalized ventricle volume at each
future visit was computed. For all predictions, authors used a radial basis function (RBF) kernel SVM,
of which the C-parameter was set to C = 0.5 and gamma to the reciprocal of the number of features.
All features were normalized to zero mean and unit standard deviation.
Confidence Intervals: Bootstrap resampling (n = 100) of the training set.
Repository link: https://github.com/tadpole-share/tadpole-algorithms/tree/master/
tadpole_algorithms/models/ecmeb
Team: FortuneTellerFish (Members: Alexandra Young, Institutions: University College London,
UK, King’s College London, UK)
Feature selection: Manual
Selected features: Age at assessment, age at scan, APOE4 status, education, gender, MRI volumes
(ventricles, hippocampus, whole brain, entorhinal, fusiform, middle temporal, all major lobes, insula,
and basal ganglia). The probability of being amyloid positive, obtained from joint mixture modelling of
CSF amyloid-beta and global AV45, was also included as a feature. Two key features, disease subtype
and stage, were derived from the Subtype and Stage Inference (SuStaIn) model based on the MRI
features [46].
Missing data: Imputed by averaging over the k-nearest neighbours with k = 5
Confounder correction: Brain volumes were corrected for age, intracranial volume and field strength
using linear regression. Parameters for the linear regression were estimated based on amyloid-negative
controls.
Method category: Data-driven disease progression models + statistical regression
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Prediction method: For ADAS-Cog13 and Ventricle prediction, a linear mixed effects model was used
which used a different set of fixed/random effects, depending on the submission:
• FortuneTellerFish-Control : For Ventricles, fixed effects were age at scan and gender. For
ADAS-Cog13 and MMSE the fixed effects were age at scan, education, APOE status and amyloid
positivity. For all target measures, there was one random effect per subject.
• FortuneTellerFish-SuStaIn : two additional fixed effects from the SuStaIn model: subtype and
stage.
For the prediction of clinical diagnosis, a multiclass error-correcting output codes (ECOC) classifier
based on SVMs was trained with the following inputs: age at assessment, age at scan, APOE status,
amyloid positivity, gender, education, SuStaIn subtype and stage, ADAS-Cog13, MMSE and ventricle
volume. For diagnosis prediction at future timepoints, the forecasted values for ADAS-Cog13, MMSE
and Ventricle volume were used as input to the classifier.
Team: Frog (Members: Keli Liu, Christina Rabe, Paul Manser Institution: Genentech,
USA)
Feature selection: Automatic using the Xgboost package [47]
Selected features: Cognitive tests (ADAS-Cog13, CDRSB, MMSE, RAVLT), clinical diagnosis, MRI
measurements, FDG PET measurements, APOE status and CSF measurements. For each longitudinal
measurement (e.g. test scores and MRI), the following transformations were computed and used to
augment the original feature set: most recent measurement, time since most recent measurement, the
historical highest (lowest) measurement, time since the historical highest and lowest measurement, and
the most recent change in measurement.
Missing data: Xgboost package automatically deals with missing data through inference based on
reduction of training loss.
Confounder correction: None
Method category: Statistical prediction using regression
Prediction method: Flexible models and features were chosen automatically using gradient boosting
(Xgboost package). Different models were trained for the following forecast windows: 0-8 months, 9-15,
16-27, 28-39, 40-60, >60 (given windows are for clinical status prediction, slightly different windows
used for ADAS-Cog13 and ventricular volume prediction) . Variable importance scores from Xgboost
suggest that MRI features play a bigger role in models trained for longer forecast windows.
Confidence Intervals: Standard deviation for prediction error was estimated based on cross validation
(on training set). Normality of prediction errors was then assumed to construct prediction intervals
based on estimated standard deviation.
Team: GlassFrog-LCMEM-HDR (Members: Steven Hill1, James Howlett1, Robin Huang1,
Steven Kiddle1, Sach Mukherjee2, Anas Rouanet1, Bernd Taschler2, Brian Tom1, Simon White1, Insti-
tutions: 1MRC Biostatistics Unit, University of Cambridge, UK; 2German Center for Neurodegenerative
Diseases (DZNE), Bonn, Germany)
Feature selection:
• MSM: Automatic, by selecting features which passed a likelihood ratio test when compared against
a model with no covariates.
• LCMEM: Manual
• HDR: Automatic, selected via sparse Lasso regression.
Selected features:
• MSM: D2 - gender, age, education, ADAS-Cog13, diagnosis, MMSE, CDRSOB, APOE status, first
5 principal components from imaging, amyloid positivity, tau level. D3 - gender, age, education,
ADAS-Cog13, diagnosis, MMSE, Ventricles/ICV
• LCMEM: ADAS-Cog13, gender, education, age at baseline
• HDR: all features were provided to the method, excluding some features with many missing values
Missing data:
• MSM: Filling with last known value, or nearest neighbour if feature was never observed.
• LCMEM: Complete case analysis (assumption that missing data are missing at random)
• HDR: Imputation using within-subject interpolation and nearest neighbour matching
Confounder correction: None
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Method category: Combination of statistical regression and data-driven disease progression models
Prediction method: The prediction of clinical diagnosis was done using a Multi-State Model (MSM).
Multi-state models (MSMs) [48] are continuous-time Markov chain models, here with states correspond-
ing to CN, MCI, AD, and transition rates estimated from the data using covariates selected as described
above. The model accounts for noise in the historical diagnostic labels. Predictions for a given forecast
month were made using the last observed disease state and associated covariates.
Prediction of ADAS-Cog13 was done using a Latent class mixed effects model (LCMEM). The model
used four latent classes, where class membership probability was modelled via a multinomial logistic.
For each latent class a specific linear mixed effects model defined a Gaussian latent process, with class-
specific fixed effects, random effects for intercept, slope and square slope, and Gaussian noise. Age at
baseline, gender and education were also included as covariates. Finally, a Beta cumulative distribution
link function was used (and estimated simultaneously) between ADAS-Cog 13 and the latent process, to
account for the departure from the Gaussian assumption on the outcome. The number of latent classes
was optimised with the Bayesian Information Criterion (BIC).
Prediction of Ventricle volume was done using high-dimensional regression (HDR) and disease
state-specific slope models: Subject-specific slopes were obtained by a combination of Lasso regression
and shrinkage towards disease-state-specific shrinkage targets. Conversion times, from one disease state
to another, were forecasted using the MSM model.
Confidence Intervals: LCMEM: the 50% confidence intervals for ADAS-Cog13 were obtained using a
bootstrap approach. HDR: Confidence intervals were set as percentages of the predicted values.
Team: GlassFrog-SM (members and affiliations as above)
Feature selection: Manual
Selected features: ADAS-Cog13, Ventricles/ICV, age at visit, APOE status, education, diagnosis
Missing data: For training, complete case analysis was performed. For prediction, imputation was
performed for missing outcomes using a linear model with age, education, diagnosis and APOE status
as covariates.
Confounder correction: None
Method category: Combination of statistical regression and data-driven disease progression models
Prediction method: The prediction of clinical diagnosis was using MSM models as in GlassFrog-
LCMEM-HDR. The prediction for ADAS-Cog13 and Ventricles used a Slope Model (SM), which used
a quadratic function to model the slope of the outcome variable as a function of the current outcome
value and covariates. Covariates used were age at visit, education and APOE status.
Confidence Intervals: SM: Confidence intervals were set as percentages of the predicted values.
The percentages used were manually selected and depended on the missingness of covariates for each
individual.
Team: GlassFrog-Average (members and affiliations as above)
Prediction method: The prediction of clinical diagnosis was using MSM models as in GlassFrog-
LCMEM-HDR. For ADAS-Cog13 and Ventricles an ensemble approach was used that averaged the
predictions from three methods: LCMEM, HDR and SM, as described above. Confidence interval
bounds were also averaged.
Team: IBM-OZ-Res (Members: Noel Faux, Suman Sedai, Institution: IBM Research Australia,
Melbourne, Australia)
Feature selection: using boosting regression
Selected features: Ventricle volume, AV45, FDG PET, cognitive tests, clinical diagnosis, age
Missing data: Imputed with zero; observations with missing ventricle volume are dropped.
Confounder correction: None
Method category: Machine Learning
Prediction method: A stochastic gradient boosting regression machine (GBM) was used to predict
Ventricle Volume, with a Huber loss function. To reduce overfitting, a shrinkage mechanism was
adopted, where the response of each tree is reduced by a factor of 0.01. Independent predictions were
made for each individual visit, and averaged when a subject had more than one visit. For the prediction
of clinical status, a similar GBM model was adopted, but with a multinomial deviance loss function.
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Team: ITESMCEM (Members: Javier de Velasco Oriol1, Edgar Emmanuel Vallejo Clemente1,
Karol Estrada2. Institution: 1Instituto Tecnolo´gico y de Estudios Superiores de Monterrey, 2Brandeis
University)
Feature selection: Manual
Selected features: Demographics, MRI volumes, FDG PET and all cognitive tests
Missing data: Imputation using the mean of previous values of that patient, otherwise mean across all
patients.
Confounder correction: None
Method category: Machine learning
Prediction method: ADAS-Cog13 is predicted with a Lasso model with α = 0.1. Ventricles are
predicted using a Bayesian ridge regression. Clinical diagnosis is predicted using two different Random
Forest models, one which selected between CN and either MCI or AD and the second which in turn
predicted between MCI and AD for those selected as non-CN. The predictions for all target variables
made use of a transition model, which predicted the next timepoint given the current one, until all
60 monthly predictions were made. The transition model was implemented using a total of 29 Lasso
models.
Confidence Intervals: They were calculated by sampling the test samples multiple times, evaluating
the performance of the model with those samples and analyzing the CIs supossing a Gaussian distribu-
tion and the corresponding t-distribution.
Team: lmaUCL (Members: Leon Aksman, Institution: University College London, UK)
Feature selection: Manual
Selected features: Diagnosis, gender, education, APOE4 status and MMSE.
Missing data: Imputation using regression over ventricles and demographics (age, gender, education)
Confounder correction: None
Method category: Statistical regression and machine learning
Prediction method: For ADAS-Cog13 and Ventricles, a multi-task learning model was used with
similar trajectories across subjects. The regression model was a linear model over age, but dependencies
between different subjects were modelled through a special prior structure over the coefficients of
the linear model. The prior structure has hyperparameters that control for the amount of coupling
across subjects, and are optimised through empirical Bayes. Clinical diagnosis was predicted using
the ADAS-Cog13 trajectory estimates plus a simple estimate of the mean and standard deviation of
ADAS-Cog13 in each diagnostic group (AD/MCI/CN). Each ADAS-Cog13 prediction was then assigned
a probability of belonging to each group. Three different submissions were made:
• lmaUCL-Std: used only last available diagnosis as covariate
• lmaUCL-Covariates: as above, but also used gender, education, APOE status and MMSE as
covariates
• lmaUCL-halfD1: trained only on half of the D1 dataset, but allowed for longer training time of 10
hours.
Confidence Intervals: Both the multi-task learning and clinical diagnosis models are probabilistic,
providing estimates of predictive mean and standard deviation assuming a normal distribution. These
were converted to confidence intervals using the inverse normal CDF.
Publication link: https://doi.org/10.1002/hbm.24682
Repository link: https://github.com/LeonAksman/bayes-mtl-traj
Team: Mayo-BAI-ASU (Members: Cynthia M. Stonnington1, Yalin Wang2, Jianfeng Wu2,
Vivek Devadas3, Institution: 1Mayo Clinic, Scottsdale, AZ, USA, 2School of Computing, Informatics
and Decision Systems Engineering, Arizona State University, USA, 3Banner Alzheimer’s Institute,
Phoenix, AZ, USA)
Feature selection: Manual, from clinical experience
Selected features: Age, PET(AV45, AV1451, FDG), hippocampal volume/ICV, ventricle volume/ICV,
diagnosis, cognitive tests (ADAS11, ADAS-Cog13, MMSE, RAVLT, MOCA, Ecog), amyloid-beta, tau,
phosphorylated tau, APOE status. All features except age were z-score normalised.
Missing data: Imputation with zero.
Confounder correction: None
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Method category: Statistical regression
Prediction method: ADAS-Cog13 and Ventricles were forecasted using a linear mixed effects model,
using all features as fixed effects and one random effect per subject (intercept). Training used all visits,
but the forecasts only used the last visit. Clinical diagnosis was predicted with a similar model, by
converting to CN/MCI/AD to a categorical variable (1/2/3).
Team: Orange (Members: Clementine Fourrier, Institution: Institut du Cerveau et de la
Moelle e´pinie`re, ICM, Paris, France)
Feature selection: Manual, through knowledge from literature
Selected features: demographics (age, education, gender), cognitive tests (ADAS11, CDSRB,
MMSE), imaging(AV45 PET, FDG PET, hippocampus size, cortical thickness) and molecular markers
(phosphorylated tau to amyloid-beta ratio, total tau, CMRgl, HCI)
Method category: Decision tree of a clinician
Prediction method: This method is based on the decision tree of a clinician. It looks at the latest
available visit for a patient, and based on the value of the selected features, it predicts a duration to
conversion. The duration to conversion depends on the initial clinical diagnosis and the other available
data. Depending on the initial diagnosis, the algorithm assumes the patient will convert within a
certain time period, and this time period is modulated by the available data about the patient. In that
regard, the algorithm does not need to account for missing values. The ADAS-Cog13 and Ventricle
measures at each month are computed assuming a linear evolution between the current time point and
the conversion date.
Team: Rocket (Members: Lars Lau Raket, Institutions: H. Lundbeck A/S, Denmark; Clin-
ical Memory Research Unit, Department of Clinical Sciences Malm, Lund University, Lund, Sweden )
Feature selection: Manual
Selected features: ADAS-Cog13, baseline diagnosis, and APOE4 carrier status.
Missing data: APOE4: Imputed using median number of alleles per baseline diagnostic group. Missing
ADAS-Cog13 scores were imputed using multivariate imputation by chained equations based on age,
sex, diagnosis and cognitive tests.
Confounder correction: None
Method category: Statistical regression and data-driven disease progression modelling
Prediction method: Prediction of ADAS-Cog13 is done through a latent-time non-linear mixed-effects
model, where the trajectory is parameterised using an exponential function. The time shift is built from
a fixed effect shift relative to time since baseline for different diagnostic groups (e.g. AD patients will
be shifted to be later in the course of cognitive decline) and a random effect shift for each subject. The
model also includes APOE status as a fixed effect that modifies rate of decline. This disease progression
modeling methodology along with several extensions is presented in [49]. Prediction of Ventricles/ICV
uses a linear mixed-effects model using an integrated B-spline basis (5 knots + intercept) in predicted
ADAS-Cog13 disease time. A random intercept is included per subject. Prediction of clinical diagnosis
is based on kernel density estimation of the states (CN/MCI/AD) across the disease time from the
ADAS-Cog13 model.
Confidence Intervals: Prediction intervals conditioned on the predicted disease time of the subject
were derived based on the estimated variance-covariance matrix of the model. Because of the monotone
nature of cognitive decline, and to heuristically compensate for the conditioning on disease time, the
upper limit of the prediction interval was multiplied by 1.5.
Publication link: https://doi.org/10.1101/2019.12.13.19014860
Team: SBIA (Members: Aristeidis Sotiras, Guray Erus, Jimit Doshi, Christos Davatzikos,
Institution: Center for Biomedical Image Computing and Analytics, University of Pennsylvania)
Feature selection: Manual
Selected features: demographics, cognitive tests, diagnosis, MRI features (Freesurfer cross-sectional).
Imaging indices (SPARE-AD and SPARE-MCI) that summarise brain atrophy patterns were estimated
through support vector machines with linear kernels. Another index representing brain age (SPARE-BA)
was estimated using a regressor model applied to imaging features.
Missing data: Features and time-points with missing data were not included
Confounder correction: Age, gender, APOE4, education, and SPARE scores were used as covariates
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in the linear mixed effects models. Also, the regression model was applied separately on different
diagnosis groups.
Method category: Statistical regression and machine learning
Prediction method: A linear mixed effects model was used to forecast the SPARE indices for future
timepoints. For diagnosis predictions, authors used class probability distribution estimations based on
the forecasted SPARE-AD score. For the prediction of ADAS-Cog13 and Ventricles, linear mixed effects
models were used, with age, gender and SPARE scores as covariates.
Team: SmallHeads – BigBrains (Members: Jacob Vogel, Andrew Doyle, Angela Tam, Alex
Diaz-Papkovich, Institution: McGill University, Montreal, Canada)
Feature selection: Automatic
Selected features:
• SmallHeads-NeuralNetwork : All features in the TADPOLE spreadsheet were considered, as
long as they had less than 50% missing data. This resulted in a final set of 376 features. Features
were normalised to zero mean and unit variance.
• SmallHeads-LinMixedEffects : All features were normalised to zero mean and unit variance. A
LASSO feature selection algorithm with ADAS-Cog13 and Y variable was used to select the best
features, which were required to have a weight greater than 0.001. 10-fold cross-validation was
used to estimate the best LASSO parameters.
Missing data: Imputed using 5-nearest neighbour method, using Euclidean distance (FancyImpute
0.0.4)
Confounder correction: None
Method category: Machine learning
Prediction method:
• SmallHeads-NeuralNetwork: A Deep fully connected neural network was trained to predict the
future diagnosis using the selected features and time until future timepoint as input. Network has
5 fully-connected layers with Leaky ReLU activations. Each layer has 512, 512, 1024, 1024 and 256
neurons, with softmax layer at output. Training used P(0.5) dropout using the Adam optimiser,
based on a class-unweighted categorical cross-entropy loss function.
• SmallHeads-LinMixedEffects: Only ADAS-Cog13 was predicted with a linear mixed effects model,
using months since baseline as an interaction term. A random (subject — time) effect was also
added, allowing variable subject-specific slopes over time.
Repository link: https://github.com/SmallHeads/tadpole
Team: SPMC-Plymouth (Members: Emmanuel Jammeh, Institution: University of Ply-
mouth, UK)
Feature selection: Automatic – Authors used the WEKA (https://www.cs.waikato.ac.nz/ml/
weka/) machine learning tool.
Selected features: Age, gender, education, ApoE4, CDRSB, ADAS11, MMSE, RAVLT, Moca, Ecog,
Hippocampus, WholeBrain, Entorhinal, MidTemp, FDG, AV45, PIB, ABETA, TAU, PTAU
Missing data:
Confounder correction: None
Method category: Machine learning
Prediction method: A machine learning classifier based on k-nearest neighbours, Naive Bayes,
Random Forest and SVM was used to predict the clinical diagnosis. ADAS-Cog13 and Ventricle volume
were not predicted. Two predictions were made, SPMC-Plymouth1 and SPMC-Plymouth2, but the
authors could not be contacted to provide details on the differences between the two.
Team: Sunshine (Members: Igor Koval, Stanley Durrleman, Institution: Institut du Cerveau et de
la Moelle e´pinie`re, ICM, Paris, France)
Feature selection: Semi-automatic – An initial set of 60 features was selected by a clinical expert.
Out of this set, the features that had more than 30% missing data were removed. A final subset of
features was chosen based on cross-validation results using trial and error.
Selected features: Age, APOE status, MMSE, ADAS-Cog13, RAVLT immediate and CDRSOB
Missing data: Imputed using mean value
Confounder correction: None
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Method category: Statistical regression and machine learning
Prediction method: A linear model was used to predict future values of ADAS-Cog13 and Ventricles,
as well as other cognitive tests: MMSE, RAVLT and CDRSOB. For the prediction of clinical diagnosis,
forecasted values of the previous five measures were used as input to an SVM. APOE4 status and
education were also used as inputs to the SVM. Adding extra features did not seem to increase prediction
scores based on cross-validation. Two submissions were made:
• Sunshine-Conservative: CN and AD subjects were forecasted to have the same diagnosis (i.e. no
conversion) for all future timepoints, after observing that a small proportion of them convert after
1 year.
• Sunshine-Std: Without the above modification.
Team: Threedays (Members: Paul Moore1, Terry J. Lyons1, John Gallacher2, Institution:
1Mathematical Institute, University of Oxford, 2Department of Psychiatry, University of Oxford, UK)
Feature selection: Manual
Selected features: Age, months since baseline, gender, race, marital status, diagnosis, cognitive
tests (MMSE, CDRSB, ADAS11, ADAS-Cog13, RAVLT immediate, learning, forgetting and percent
forgetting, FAQ) and APOE status.
Missing data: Random forest method deals with missing data automatically, by finding optimal splits
with existing data only.
Confounder correction: None
Method category: Machine learning
Prediction method: For the prediction of clinical diagnosis, two random forest models are trained,
the first for transitions from a healthy diagnosis, and the second for transitions from an MCI diagnosis.
For AD individuals, authors assume that the diagnosis will not change. The training data was generated
by ordering each participant’s data by time, then associating the feature vector x with diagnosis y for
each time horizon available for the participant. ADAS-Cog13 and Ventricles were not predicted. The
PLOS paper describes a method similar to the original, but using different predictors and a single
random forest.
Publication link: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.
0211558
Team: Tohka-Ciszek (Members: Jussi Tohka, Robert Ciszek Institution: A.I. Virtanen Institute
for Molecular Sciences, University of Eastern Finland, Finland)
Feature selection: Manual
Selected features:
• D2: diagnosis, gender, education, race, marital and APOE status, age, cognitive tests (CDRSB,
ADAS11, ADAS-Cog13, MMSE, RAVLT learning, immediate and perc. forgetting, FAQ, MOCA,
all Ecog), MRI volumes (ventricles, hippocampus, whole brain, entorhinal, fusiform, middle tem-
poral, ICV)
• D3: diagnosis, age, gender, education, ethnicity, race, marital status, ADAS-Cog13, MMSE, MRI
volumes as above
Missing data:
• SMNSR : A sub-model is trained for each subset of features which occurs without missing
values. A specific catch-all subset is used for patients for which well performing whole measurement
set cannot be found. For this data set, values are imputed using the median of k-nearest neighbours
or replaced with -1.
• RandomForestLin : Imputation using mean values from the timepoints of the same subject
(D2) or diagnostic category (for D3).
Confounder correction: None
Method category: Machine learning
Prediction method:
• Tohka-Ciszek-SMNSR : For ADAS-Cog13 prediction, a Sparse Multimodal Neighborhood
Search Regression was used. This method first uses a linear regression model to estimate ADAS-
Cog13 from the selected features belonging to the current subject and neighbour subjects, esti-
mated based on a K-nearest neighbour algorithm. The forecasts from this model were passed to a
gradient-boosted tree model, providing the final prediction. Ventricles and clinical diagnosis were
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not predicted.
• Tohka-Ciszek-RandomForestLin : To predict ADAS-Cog13 and Ventricles, a weighted average
of two models was used: 1) a unimodal linear model 2) a linear model taking the response variable
from the final time point and predictor variables from a time point before that. For diagnosis
prediction, a random forest was trained using ADAS-Cog13, Ventricle/ICV, age and APOE status.
Confidence Intervals: Predicted score +/- cross-validation MAE.
Repository link: https://github.com/jussitohka/tadpole(RandomForestLin),https:
//github.com/rciszek/SMNSR (SMNSR)
Team: VikingAI (Members: Bruno Jedynak1, Kruti Pandya1, Murat Bilgel2, William Engels1,
Joseph Cole1, Institutions: 1Portland State University, USA, 2Laboratory of Behavioral Neuroscience,
National Institute on Aging, National Institutes of Health, Baltimore, MD, USA)
Feature selection: Manual
Selected features: Diagnosis, age, ADAS-Cog13, CDRSOB, MMSE, RAVLT immediate, tau,
ventricles/ICV, hippocampus/ICV. Features were normalized prior to model fitting.
Missing data: Method automatically deals with missing data through Bayesian inference
Confounder correction: None
Method category: Data-driven disease progression model
Prediction method: For the prediction of ADAS-Cog13 and Ventricles, a latent-time parametric
model was used, estimating a linear subject-specific model over the age of subjects, resulting in a disease
progression score (DPS). The trajectories of biomarkers were assumed to be either sigmoidal functions
or a sum of logistic basis functions over the DPS space. Some feature-specific parameters are estimated
from the features’ histograms, while the rest are optimized. Priors over the parameters to be optimized
are set a-priori. Two submissions were made:
• VikingAI-Sigmoid: sigmoidal function as biomarker trajectory
• VikingAI-Logistic: the sum of 15 logistic basis functions as the biomarker trajectory
Confidence Intervals: Bayesian predictive intervals
In addition to the above entries, the organisers also included several benchmark algorithms as
well as some extra predictions: (1) two ensemble predictions averaging all the predictions submitted by
the participants, and (2) 62 randomised predictions which can tell how likely it is that top submissions
obtained their scores due to chance, by building a null distribution of the performance metrics. The
Source code of some benchmarks (BenchmarkLastVisit, BenchmarkMixedEffectsAPOE, Bench-
markSVM ) was offered to participants before the conference deadline, as a starting point for making
predictions.
Benchmark: BenchmarkLastVisit (Authors: Daniel Alexander, Razvan Marinescu, Institu-
tions: University College London, UK, Massachusetts Institute of Technology, USA)
Feature selection: None
Selected features: ADAS-Cog13, ventricle volume, diagnosis
Missing data: Not required
Confounder correction: None
Method category: Regression
Prediction method: For ADAS-Cog13 and Ventricles, the last available measure is used, otherwise
the average for the current diagnostic group is used. Confidence intervals are set to default widths
of 2 for ADAD13 and 0.001 for Ventricles/ICV. For prediction of clinical diagnosis, the last available
diagnosis is used with probability 100%, and 0% probability for the other diagnoses.
Confidence Intervals: hard-coded
Repository link: https://github.com/noxtoby/TADPOLE/blob/master/evaluation
Benchmark: BenchmarkMixedEffects (Author: Razvan Marinescu, Daniel Alexander, Insti-
tution: University College London, UK, Massachusetts Institute of Technology, USA)
Feature selection: None
Selected features: ADAS-Cog13, ventricle volume, diagnosis (, APOE status)
Missing data: Automatic, since model is univariate.
Confounder correction: APOE status was used as covariate in the linear mixed effects model
Method category: Regression
Prediction method: Linear Mixed Effects Model with age at visit as the predictor variable. Model
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was fitted independently for ADAS-Cog13 and Ventricles. Predictions for clinical diagnosis were derived
from the corresponding ADAS-Cog13 forecasts, using three Gaussian likelihood models for CN, MCI
and AD. The likelihoods for diagnostic classes were finally converted to probabilities by normalisation.
Default values were used for confidence intervals. Two predictions were made:
• BenchmarkMixedEffectsAPOE: the slope of the population trajectory was stratified by APOE
status
• BenchmarkMixedEffects: as above but without APOE
Confidence Intervals: hard-coded
Repository link: https://github.com/noxtoby/TADPOLE/blob/master/evaluation
Benchmark: BenchmarkSVM (Author: Esther Bron, Institution: Erasmus MC)
Feature selection: Manual
Selected features: Diagnosis, age, ADAS-Cog13, Ventricles, ICV, APOE
Missing data: Fill-in using average value of biomarker from past visits of the same subject, otherwise
population average.
Confounder correction: None
Method category: Machine Learning
Prediction method: For the prediction of clinical diagnosis, a probabilistic SVM was used based
on the selected features, while for the prediction of ADAS-Cog13 and Ventricles, a Support Vector
Regressor (SVR) was used. All SVM/SVRs used linear kernels. Default values were used for confidence
intervals.
Confidence Intervals: hard coded
Repository link: https://github.com/noxtoby/TADPOLE/blob/master/evaluation
Benchmark: RandomisedBest (Author: Razvan Marinescu, Institutions: University College
London, UK, Massachusetts Institute of Technology, USA)
Feature selection: Manual
Selected features: Diagnosis, age, ADAS-Cog13, Ventricles, ICV
Missing data: Fill-in using last available measurement
Confounder correction: None
Method category: Regression
Prediction method: The method aims to construct a null distribution of values, to check how likely
a high score could be obtained by chance alone. Starting from the simplest prediction method, i.e.
BenchmarkLastVisit which simply takes the last available measure, 62 randomised predictions were
created (as many as the total number of predictions in D2) by adding random perturbations to the
predictions. For Diagnosis prediction, the probability of controls and MCI subjects to convert within 1
year was computed from ADNI historical data, and then each control and MCI was randomly chosen to
convert with those probabilities. For ADAS-Cog13 and Ventricles, random uniform noise was added to
the predictions as follows:
• ADAS: new adas ∼ last available adas + U(0, 7)
• Ventricles: new ventricles ∼ last available ventricles + U(0, 0.01)
The new values new adas and new ventricles, as well as the new diagnosis, were assigned to all 60
months, thus assuming no change across the 60 month predictions. All 62 different predictions were
evaluated, and the RandomisedBest entry shows the best scores obtained by all 62 submissions in each
category separately.
Confidence Intervals: hard-coded
Repository link: https://github.com/noxtoby/TADPOLE/blob/master/evaluation
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Supplementary material
A Creating the D1-D4 datasets
The data used from ADNI consists of: (1) CSF markers of amyloid-beta and tau deposition; (2) various
imaging modalities such as magnetic resonance imaging (MRI), positron emission tomography (PET)
using several tracers: Fluorodeoxyglucose (FDG, hypometabolism), AV45 (amyloid), AV1451 (tau) as
well as diffusion tensor imaging (DTI); (3) cognitive assessments acquired in the presence of a clinical
expert; (4) genetic information such as alipoprotein E4 (APOE4) status extracted from DNA samples;
and (5) general demographic information. Extracted features from this data were merged together into
a final spreadsheet and made available on the LONI ADNI website.
The imaging data has been pre-processed with standard ADNI pipelines. For MRI scans, this included
correction for gradient non-linearity, B1 non-uniformity correction and peak sharpening. [ADNI MRI
pre-processing]. Meaningful regional features such as volume and cortical thickness were extracted using
the Freesurfer cross-sectional and longitudinal pipelines [50]. Each PET image (FDG, AV45, AV1451)
had their frames co-registered, averaged across the six five-minute frames, standardised with respect to
the orientation and voxel size, and smoothed to produce a uniform resolution of 8mm full-width/half-max
(FWHM) (see http://adni.loni.usc.edu/methods/pet-analysis/pre-processing/). Standardised
uptake value ratio (SUVR) measures for relevant regions-of-interest were extracted after registering the
PET images to corresponding MR images using the SPM5 software [51]. Further details have been
provided in the ADNI procedures manual. DTI scans were corrected for head motion and eddy-current
distortion, skull-stripped, EPI-corrected, and finally aligned to the T1 scans using the pipeline from [52].
Diffusion tensor summary measures were estimated based on the Eve white-matter atlas [53].
In addition to the standard datasets, we also created three leaderboard datasets LB1, LB2 and LB2
which mimick the D1, D2 and D4 datasets. These datasets were used by participants to preliminarily
evaluate their algorithms before the competition deadline, and to compare their results on the leaderboard
system (https://tadpole.grand-challenge.org/Leaderboard/).
B Statistical testing
B.1 Differences in MAUC scores
For analysing whether the MAUC scores obtained by top algorithms are significantly different, we per-
formed a bootstrapped hypothesis test [54], since the significance test for comparing two AUC scores [55]
does not extend to multiple classes. For two TADPOLE entries A and B, where A scored better than B
on the full D4 test set, we want to confirm either the null hypothesis H0 : mauc(A) = mauc(B) or the
alternative hypothesis H1 : mauc(A) > mauc(B). We then proceed as follows:
• Sample N = 50 random bootstraps Di of the D4 test set with replacement.
• Compute the mauc(A,Di) and mauc(B,Di) based on the bootstrapped dataset. Repeat for all N
bootstraps.
• Compute the p-value as ∑i I[mauc(A,Di) < mauc(B,Di)]/N , which is the proportion of boot-
strapped datasets where A performed worse than B.
• Accept/reject H0 based on a 5% significance level.
B.2 Differences in MAE scores
For comparing differences in MAE scores, we applied the non-parametric Wilcoxon signed-rank test on
paired samples of absolute errors across all visits of the D4 subjects. We chose the non-parametric
Wilcoxon test because the input samples are not normally distributed, as they represent absolute errors
and are always positive. We report results based on a 5% significance level.
B.3 Differences between D2 and D3 forecasts
For comparing differences between the scores obtained by two algorithms on D2 vs D3 forecasts, we use
an approach similar to comparing MAUC scores (section 8.4.2).
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C Supplementary Results
Overall Diagnosis ADAS-Cog13 Ventricles (% ICV)
Submission Rank Rank MAUC BCA Rank MAE WES CPA Rank MAE WES CPA
Billabong-UniAV45 1 1 0.719 0.624 1-2 8.71 8.55 0.33 3-4 3.49 3.40 0.50
Billabong-Uni 2 2 0.717 0.621 1-2 8.71 8.55 0.33 3-4 3.49 3.40 0.50
Billabong-MultiAV45 3 3 0.661 0.562 3-4 12.95 12.71 0.42 1-2 3.16 3.08 0.47
Billabong-Multi 4 4 0.658 0.552 3-4 12.95 12.71 0.42 1-2 3.16 3.08 0.47
Simple-SPMC-Plymouth2 - 5 0.500 0.504 - - - - - - - -
Simple-SPMC-Plymouth1 - 6 0.500 0.499 - - - - - - - -
Table C.1: Results on custom prediction sets from two teams: Billabong and SPMC-Plymouth. SPMC-
Plymouth predicted fewer subjects due to an incomplete submission, while Billabong used a prediction set
similar to D3, but filled in missing data for cognitive tests and MRI with the last available measurement.
SPMC-Plymouth only submitted predictions for clinical diagnosis, and obtained an MAUC score of 0.5.
Results from Billabong show higher MAUC and BCA in diagnosis prediction compared to D3, but lower
performance for ADAS-Cog13 and Ventricle volume prediction. Bold entries show best scores in this
category.
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Figure C.1: Distribution of performance metrics for clinical diagnosis (MAUC and BCA), ADAS-Cog13
(MAE, WES and CPA) and ventricle volume (MAE, WES and CPA) on the longitudinal D2 prediction
set. For each entry, we plot the distribution of performance metrics derived using 50 bootstrap data sets
drawn from the D4 test set. The submissions (rows) are in the same order as in Table 2. Entries are
missing where teams did not make predictions for a particular target variable.
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Figure C.2: Box plots of performance metrics for clinical diagnosis (MAUC and BCA), ADAS-Cog13
(MAE, WES and CPA) and ventricle volume (MAE, WES and CPA) on the cross-sectional D3 prediction
set. The submissions (rows) are in the same order as in Table 3. Some entries are missing because teams
did not make predictions for those target variables.
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Figure C.3: For D2 submissions, we show scatter plots of pairs of performance metrics for (top row)
clinical diagnosis, (middle row) ADAS-Cog13 and (bottom row) Ventricles. Each dot is a participant
submission, coloured according to the type of prediction algorithm used. Correlation coefficients and
p-values are given above each subplot. A few outlier submissions with ADAS MAE > 20, ADAS WES
> 40 or Ventricle WES > 3 were excluded from the analysis.
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Figure C.4: For D3 submissions, we show scatter plots of pairs of performance metrics for (top row)
clinical diagnosis, (middle row) ADAS-Cog13 and (bottom row) Ventricles. Each dot is a participant
submission, coloured according to the type of prediction algorithm used. Correlation coefficients and
p-values are given above each subplot. A few outlier submissions with ADAS MAE > 20, ADAS WES
> 40 or Ventricle WES > 3 were excluded from the analysis.
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Figure C.5: Bias in prediction of clinical diagnosis for MCI subjects only. X-axis shows individual
subjects with designated MCI status at the clinical visit in D4, while the Y-axis shows TADPOLE
algorithms. Red represents subjects which were predicted as CN with true diagnosis of MCI, while blue
represents subjects predicted as AD with true diagnosis of MCI. Some algorithms show systematic biases
either towards CN or AD.
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Figure C.6: Bias in prediction of ADAS-Cog13. X-axis shows individual subjects with ADAS-Cog
measurements in D4, while Y-axis shows TADPOLE algorithms. Red represents under-estimates while
blue represents over-estimates. Most algorithms under-estimate ADAS-Cog measurements.
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Figure C.7: Bias in prediction of ventricle volume. X-axis shows individual subjects with Ventricle
volume measurements in D4, while Y-axis shows TADPOLE algorithms. Red represents under-estimates
while blue represents over-estimates. Some algorithms systematically under-estimate or over-estimate
ventricle volume.
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Figure C.8: Distribution of ranks in clinical diagnosis MAUC for TADPOLE submissions using the
longitudinal prediction set (D2), obtained from N = 50 bootstraps of the test set (D4). More precisely,
we computed the MAUC ranks given a specific bootstrap of the test set, and then for each TADPOLE
submission (Y-axis) we plotted the number of times it achieved a specific rank. Figures C.9 – C.13 use
the same methodology.
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Figure C.9: Distribution of ranks in ADAS-Cog13 MAE for TADPOLE submissions using the longi-
tudinal prediction set (D2)
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Figure C.10: Distribution of ranks in Ventricle Volume MAE for TADPOLE submissions using the
longitudinal prediction set (D2).
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Figure C.11: Distribution of ranks in clinical diagnosis MAUC for TADPOLE submissions using the
longitudinal prediction set (D3).
48
0 5 10 15 20 25 30 35
Rank
CyberBrains
Tohka-Ciszek-RandomForestLin
Rocket
GlassFrog-SM
GlassFrog-Average
VikingAI-Logistic
EMC1-Std
BORREGOTECMTY
GlassFrog-LCMEM-HDR
SBIA
Billabong-Uni
Billabong-UniAV45
BGU-RF
BGU-RFFIX
BGU-LSTM
lmaUCL-halfD1
lmaUCL-Covariates
lmaUCL-Std
BenchmarkLastVisit
DIKU-GeneralisedLog-Std
DIKU-GeneralisedLog-Custom
DIKU-ModifiedLog-Std
DIKU-ModifiedMri-Std
DIKU-ModifiedLog-Custom
DIKU-ModifiedMri-Custom
ATRI-Biostat-MA
EMC-EB
BravoLab
ATRI-Biostat-JMM
Billabong-MultiAV45
Billabong-Multi
BenchmarkSVM
CBIL
ATRI-Biostat-LTJMM
DIVE
IBM-OZ-Res
Figure C.12: Distribution of ranks in ADAS-Cog13 MAE for TADPOLE submissions using the longi-
tudinal prediction set (D3).
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Figure C.13: Distribution of ranks in Ventricle Volume MAE for TADPOLE submissions using the
longitudinal prediction set (D3).
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